Index

Page numbers followed by an f denote figures, those followed by a t denote tables, and those followed by a b denote boxes.

AAHA pain management standards, 4, 5t
Abdominal (diaphragmatic) breathing pattern, as anesthetic depth indicator, 199
ABP. See Arterial blood pressure (ABP)
Absorbents, carbon dioxide, 179–180
Absorption, of local anesthetics, 340–341
Acepromazine
  boxers and, 291
  cardiovascular effects, 380t, 381
  in cesarean section patients, 473t
described, 44
  in GI endoscopy patients, 439
  hypotension and, 231–232
  in liver disease patients, 424
  in neonatal and geriatric patients, 494
  in neurological disease patients, 407
  ocular effects, 467t
  in orthopedic patients, 500
  preanesthetic use, 279, 282t
  in respiratory disease patients, 388–389, 393, 396
  in rodents and rabbits, 316t
Acetaminophen
  for chronic pain, 154
  codeine combined with, 111
  COX-3 inhibition, 120
dosage ranges, 126t
  overview of, 127–128
Acetylcholinesterase, 76, 80–81
Acid, defined, 241
Acid-base balance, 240–258
  analysis
    anion gap approach, 251–253, 252t
    base excess approach, 251
    strong ion approach, 253–258, 254t
    base excess modification, 256–257, 256t, 257t
    effective SID modification, 255–256
    SID (strong ion difference), 253–255
    simplifications of, 255
    simplified SIG modification, 257–258
    traditional approach, 247–251, 248t, 249f
    expected compensatory changes, 250t
    limitations of approach, 250–251
    mixed disorders, 250
    simple disorders, 248–249, 249f
    causes of disorders, 248t
    compensatory changes, 249, 249f, 250t
    fluid balance assessment and, 267
    regulation of, 240–247
  chemical buffering, 243–245
    bicarbonate buffer system, 243
    factors influencing intracellular, 244–245
    isohydric principle and, 245
    phosphate buffer system, 244
    protein buffer system, 244
    renal, 245–247
respiratory, 245
temperature effects, 247
terminology, 241–242
Acid dissociation constant (K_a), 241
Acidemia, 242
Acidosis. See also Acid-base balance
defined, 242
strong ion difference (SID), 254t
Acupuncture
for chronic pain, 157
electrical stimulation, 136–137
history, 132–133
mechanism of analgesic action, 135
needles, 137
overview, 131–132
perioperative use, 138–140
cardiopulmonary resuscitation, 140
for impaired intestinal function, 140
intraoperative assisted anesthesia, 138
postoperative pain control, 139–140
preoperative preparation, 138
skepticism on effectiveness of, 132
theory, 133–135
organs and meridians, 133–134
points, 134–135
point stimulation, 135
types, 136
veterinary, 137–138
Acute pain, assessment of, 93–96, 95f, 97f
Addison’s disease, 455–456
Additivity, drug, 8
Adjustable pressure-limiting (APL) valve,
177–178, 178f
Adrenal gland disorders, 455–456
adrenal insufficiency, 455–456
hyperadrenocorticism, 456
pheochromocytoma, 456
Adrenal insufficiency, 455–456
Afterload, 25, 379
AG (anion gap), calculation of, 251–252, 253
Aggressive patients, anesthetic drug selection
for, 290
Agology, 83
Airway obstruction, anesthetic drug selection
and, 291
Airway pressure alarms, 194
Alarms, ventilator, 194
Aldosterone, 455
Alfentanil
dosage ranges, 106t
overview of, 111
Algometer, 93
Alkalemia, 242
Alkalization, of local anesthetics, 337–338
Alkalosis. See also Acid-base balance
defined, 242
strong ion difference (SID), 254t
Allergic reactions
anesthetic emergencies, 512–513
local anesthetics, 346–347
Allodynia
declared, 83
neuropathic pain and, 91
Alpha_2 adrenergic agonists. See also specific
drugs
analgesia, 129
cardiocirculatory effects, 380t, 381
for epidural use, 366–367
in neonatal and geriatric patients, 494
in neurological disease patients, 403
in orthopedic patients, 500
pharmacology, 44–47
renal effects, 414–415
respiratory effects, 391
Alpha_2 adrenergic antagonists, pharmacology
of, 47–48
Alphadolone, 52
Alpha-stat hypothesis, 247
Alphaxalone
for anesthesia induction, 286t
in cesarean section patients, 473t
described, 52–53
in intramuscular anesthetic protocol in cats,
285t
Alveolar air, composition of, 29–30
Alveolar mandibular nerve, desensitization of,
352, 352f
Alveolar partial pressure of carbon dioxide
(P_aCO_2), 388
Alveolar ventilation (V_a), 218–219, 387–388
Amantadine
analgesia, 130
for chronic pain, 155
dosage ranges, 129t
American Animal Hospital Association
(AAHA) pain management
standards, 4, 5t
American College of Veterinary Anesthesiologists Recommendations for Monitoring Anesthetized Patients, 14, 197
American Veterinary Medical Association Professional Liability Insurance Trust claims, 12, 12t, 14
Amethocaine cream, 341
Amiodarone, for ventricular tachycardia, 517
Amitriptyline, for chronic pain, 156
Analgesia. See also Pain management analgesic ladder, World Health Organization (WHO), 151–152, 151t defined, 83, 98 epidural (See Epidural anesthesia/analgesia) inhalation anesthetic agents, 69 multimodal, 98–99 preemptive, 99 for shock, 486 signaling and mechanisms of, 101 Analgesic adjuvants, 128–131. See also specific drugs alpha2-adrenergic agents, 129 amantadine as, 130 dosage ranges, 129t gabapentin as, 129–130 ketamine as, 129 overview, 128–129 tapendadol as, 131 tramadol as, 130–131 Analgesic reverse pyramid approach, to pain management, 152 Analgesics. See also specific drugs adjuvants, 128–131 defined, 83 in neurological disease patients, 403 ocular effects, 467t respiratory effects, 392 selection of drugs, 7–9 in small mammals, 311–314, 313t Anaphylaxis anesthetic emergencies, 512–513 from local anesthetics, 346–347 Anemia in chronic renal failure, 413–414 impact on arterial oxygen content, 217t perianesthetic fluid therapy for, 261 Anesthesia complications (See Anesthetic complications, management of) defined, 83 epidural (See Epidural anesthesia/analgesia) equipment for (See Anesthetic equipment) induction (See Induction of anesthesia) infiltration (See Infiltration anesthesia) laboratory animal (See Laboratory mammal anesthesia) liability claims, 12, 12t, 14 maintenance (See Maintenance of anesthesia) management (See Anesthesia management) physiological consequences of, 201 recovery (See Recovery from anesthesia) regional (See Regional anesthesia) topical (See Topical anesthesia) Anesthesia equipment, 158–196 anesthetic machine, 168–174 common gas outlet, 174 diagram of basic, 170f–171f flow meter, 169 gas flow within, 168–169 oxygen flash valve, 173–174 scavenging system, 171f vaporizer, 171–173 breathing systems, 174–183 nonrebreathing, 180–183, 182f, 184f rebreathing (circle system), 175–180 checkout procedure, 185, 185t–186t endotracheal tubes, 160–163, 161f, 162f, 164f laryngoscopes, 163–165, 165f malfunctions, 522, 523f medical gas supply, 165–168 cylinders, 166, 166t pressure gauge, 168 regulator, 167–168 safety, 166–167 overview, 158 safety and design standards, 158–159 scavenging system, 183–185 ventilators, 187–195 alarms, 194 control of driving gas, 192 dual-circuit, 188–192, 190f factors effecting delivered tidal volume, 193–194
rolling diaphragm system of Tafonius, 188f
setup and monitoring, 195
Anesthesia management, 274–299
anesthetic plan worksheet, 276f
balanced anesthesia approach, 279
drug protocol selection, 274, 278–279
drug selection, patient-related factors and, 288–293
for aggressive patients, 290
breed-related concerns, 291–292
for geriatric patients, 290
for neonatal or pediatric patients, 291
with preexisting diseases, 292–293
species differences, 288–289
for trauma or hemodynamically unstable patients, 292, 292t, 293t
for young, healthy patients, 289–290
drug selection, procedure-related factors, 293–298
by length of procedure, 296–298
intermediate, 298
long, 298
short, 296–297
by level of invasiveness, 293–296
invasive with mild/moderate pain, 294–295
invasive with moderate/severe pain, 295–296
minimally invasive procedures, 294
noninvasive procedures, 293–294
induction of anesthesia, 280–281, 283–284
in cats, 287t
in dogs, 286t
goals of, 283b
inhalant agents, 281
intramuscular agents, 283, 284t, 285t
intravenous agents, 283–284, 286t
local and regional techniques, 296b
maintenance of anesthesia, 284–286
goals, 287b
supplemental systemic analgesics, 296t
preanesthetic medication, 279–280
common medications in cats, 282t
common medications in dogs, 282t
goals of, 280b
steps in selecting, 281f
preanesthetic patient evaluation form, 275f
record keeping, 299
recovery from anesthesia, 286–288
injectable postoperative analgesics, 288t
oral postoperative analgesics, 289t
systematic approach to, 277f–278f
Anesthetic complications, management of, 227–239. See also Anesthetic emergencies
bradycardia and bradyarrhythmias, 228–229, 228t, 229f
hypertension, 233–234
hyperthermia, 239
hyperventilation and hypopcapnia, 238
hypotension, 231–233, 233t
hypothermia, 238–239
hypoventilation and hypercapnia, 237–238
hypoxemia, 234–237, 235t
tachycardia and tachyarrhythmias, 228t, 230–231, 230f, 231f
Anesthetic depth
inhalation anesthetic agents, 64–65
monitoring, 198–201
objective methods, 199–200
physical signs, 198–199
subjective methods, 198–199
Anesthetic emergencies, 509–527
allergic reactions, 512–513
anesthetic risk, 509–510
high-risk patients, 510
management of, 509–510
species-related, 510
cardiac arrest, 513–520
cardiovascular, 510–512
dysrhythmia, 511–512
hemorrhage and fluid loss, 510–511
delayed recovery, 522, 524
electrolyte abnormalities, 527
epidural analgesia and regional nerve block, 526–527
equipment malfunction, 522, 523f
gastroesophageal reflux and regurgitation, 524
hyperthermia, 525–526
hypothermia, 525
injuries, 526
perivascular injection, 520
respiratory insufficiency, 520–522
in small mammals, 310
Anesthetic machine, 168–174
  common gas outlet, 174
  diagram of basic, 170f–171f
  flow meter, 169
  gas flow within, 168–169
  oxygen flash valve, 173–174
  safety and design standards, 158–159
  scavenging system, 171f
  vaporizer, 171–173
  variations in, 158, 159f

Anesthetic physiology and pharmacology
  cardiovascular anatomy and physiology, 15–25
  nervous system anatomy and physiology, 35–41
  respiratory system physiology, 25–34

Anesthetic plan worksheet, 276f

Anesthetic risk, 13f, 14
  high-risk patients, 510
  management of, 509–510
  species-related, 510

Anesthetics. See also specific drugs
  defined, 83
  inhalant (See Inhalant anesthetic agents)
  injectable (See Injectable anesthetic agents)
  interactions, common, 8
  selection of drugs, 7–9

Animal welfare, five freedoms for evaluation of, 149, 149t

Anion gap (AG), calculation of, 251–252, 253

Anion gap approach, to acid-base balance, 251–253, 252t

Antagonism, drug, 8

Antiarhythmic therapy, for shock, 485, 486t

Antibiotics
  after cardiopulmonary resuscitation (CPR), 520
  prophylactic administration, 6

Anticholinergics. See also specific drugs
  cardiovascular effects, 381
  in orthopedic patients, 500
  pharmacology, 41–43
  atropine, 42–43
  glycopyrrolate, 43
  preanesthetic use, 279–280, 282t
  in respiratory disease patients, 394, 396–397

Anticonvulsants
  for chronic pain, 156
  for local anesthetic toxicity, 347

Antimicrobial activity, of local anesthetics, 328

Antinociception, 136–137

Antitussive
  butorphanol as, 114
  opioids as, 103, 111

APL (adjustable pressure-limiting) valve, 177–178, 178f

Apnea
  during anesthesia, 521
  defined, 26

Apneic threshold, 31, 521

Apneustic respiration, 26

Aquitoxis, 320

Aquatic-based rehabilitation, 144

Arachidonic acid cascade, 117f

Armadillos, 321–322

Arrhythmia
  as anesthetic emergency, 511–512
  local-anesthetic associated, 348
  with splenic masses, 446–447

Arterial blood pressure (ABP)
  as anesthetic depth indicator, 198–199
  assessment in small mammals, 309
  clinical measurement of, 209–211
    Doppler, 210
    invasive methods, 210–211
    oscillometric, 209–210
  fluid balance assessment and, 266–267
  monitoring, 208–211, 211f
  in ocular patients, 462

Arterial carbon dioxide partial pressure
  (PaCO₂), 218–222, 237–238
  acid-base balance and, 245
  cerebral blood flow and, 401f, 402
  relationship to alveolar ventilation, 489
  in traumatized and critically ill patients, 489

Arterial O₂ saturation (SaO₂), 201–203, 214–218, 217t

Arterial oxygen partial pressure (PaO₂), 201–202, 214–217, 217t

Cerebral blood flow and, 401f, 402

in traumatized and critically ill patients, 489

Arterial pressure waveform, components of normal, 211f

Arterial pulse pressure, 20
Arteries, 16
Arteriovenous anastomoses, 16
Articaine. See also Local anesthetics properties, 332t
trade name, structure, and main uses, 331t
Aspirin
annual human consumption of, 121
contraindications, 124
COX-3 inhibition, 120
dosage ranges, 126t
gastrointestinal effects of, 123
mechanism of action, 116, 120–121
overview of, 128
Aspirin-triggered lipoxin, 120
Astramorph, 376
Asystole, 513, 517, 518. See also Cardiac arrest
Atipamezole, 47–48, 286
Atracurium
in cesarean section patients, 474t
doses, 77t
in GI endoscopy patients, 440
in liver disease patients, 427
pharmacology, 78–79
in portosystemic shunt patients, 430
Atrial fibrillation, 230–231, 231f
Atrioventricular (AV) block
first degree, 229, 229f
second degree, 229
third degree, 229, 229f
Atrioventricular (AV) node, 22, 24
Atropine
for cardiopulmonary resuscitation (CPR), 517
in cesarean section patients, 473t
clinical uses, 43
dysrhythmias from, 512
intravenous dose for heart rate/rhythm abnormalities, 228t
ocular effects, 466t
in orthopedic patients, 500
pharmacokinetics and pharmacodynamics, 42–43
preanesthetic use, 279–280, 282t
in respiratory disease patients, 396
in rodents and rabbits, 315, 316t
structure, 42
Autacoids, 120
Autonomic nervous system, 40
AV block. See Atrioventricular (AV) block
AV node. See Atrioventricular (AV) node
Avogadro’s principle, 60
Axonal conduction, 40
Azotemia, 413, 416, 417
Back pressure, on vaporizer, 172–173
Badgers, 323
Bain system, 181, 182f, 183, 526
BAL (bronchial alveolar lavage), hypoxia and, 521
Balanced anesthesia, 279
Balanced electrolyte solution, 268, 481
Barbiturates. See also specific drugs
in neonatal and geriatric patients, 494
pharmacology, 51–52
methohexital sodium, 52
pentobarbital sodium, 51
phenobarbital sodium, 51
thiopental sodium, 52, 53f
Baricity, of local anesthetics, 338
Barium lime (baralyme), 179
Barometric pressure, 61
Barotrauma, 526
Base, defined, 241
Base deficit or excess (BDE), 251
Base excess approach to acid-base balance, 251
Base excess gap (BEG), 256
Bats, 320–321
BDNF (brain-derived neurotrophic factor), 89–90
Behaviors, associated with chronic pain, 150t
Bellows, 189, 191
Benzocaine. See also Local anesthetics
metabolism of, 343
topical use, 349–350
trade name, structure, and main uses, 331t
Benzodiazepine antagonists, 50
Benzodiazepines. See also specific drugs
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
cardiovascular effects, 380–381, 380t
cerebral blood flow, and intracranial pressure decrease from, 403
for induction in patients with trauma and/or hemodynamic instability, 292t
in liver disease patients, 424, 428
Benzodiazepines (cont’d)
in neonatal and geriatric patients, 493–494
in orthopedic patients, 500
pharmacology, 48–50
in respiratory disease patients, 389, 391,
396
for seizures, 403
B-endorphins, 93, 100, 101
Bicarbonate
addition to local anesthetics, 337–338
formation in red blood cells, 30
for shock, 485
Bicarbonate buffer system, 243. See also
Acid-base balance
Bier block, 359–360, 501
Bile peritonitis, 447
Biotransformation
of inhalation anesthetic agents, 65–66
of local anesthetics, 342–343
Biot’s respirations, 26
Bispectral index (BIS), 408
Bispectral Index™ (BIS) Monitoring System,
200
Bisphosphonates, for chronic pain, 157
Blink reflex, 468
Blood
anatomy and physiology, 18–19
oxyhemoglobin dissociation curve, 18f
products, 271, 273
Blood gas analysis
fluid balance assessment and, 267
of PaCO₂, 220–221
of PaO₂, 215–216
portable patient-side monitors, 216, 220–221
Blood-gas partition coefficient (PC), 64
Blood glucose, assessment during anesthesia,
226
Blood lactate concentration, as indicator of
perfusion during volume resuscitation, 267
Blood loss
as anesthetic emergency, 510–511
quantifying, 511
Blood pressure. See also Arterial blood pressure (ABP)
anesthetic complications, managing
hypertension, 233–234
hypotension, 31–233, 233t
arterial pulse pressure, 20
assessment in small mammals, 309
clinical measurement of, 209–211
Doppler, 210
invasive methods, 210–211
oscillometric, 209–210
factors determining arterial, 20, 21f
fluid balance assessment and, 266–267
formula for estimation of mean arterial, 20
mean arterial (See Mean arterial blood pressure (MAP))
monitoring, 208–211, 211f
overview of, 20
Blood products, 271, 273
plasma, 271
PRBCs, 273
whole blood, 273
Blood vessels, anatomy and physiology of, 16,
17f, 18
Blood viscosity, 19
Blood volume, defined, 258
Body surface area (BSA)/mass ratio,
288–289
Boiling point, 61–62
Bone marrow aspiration, 505
Boston approach, to acid-base balance, 250
Boxer, acepromazine and, 291
Boyle’s law, 60
Brachial plexus block
described, 332, 334, 334f
techniques
in cats, 371–373
in dogs, 357–359, 358f
Brachycephalic airway syndrome, 291, 393
Brachycephalic dogs, anesthetic drug selection
and, 291
Bradyarrhythmias, managing as anesthetic complications, 228–229, 228t
Bradycardia, managing as anesthetic complication, 228–229, 228t
Bradypnea, 26
Brain. See also Central nervous system (CNS)
anatomy, 35
physiology, 35–37
anesthetic effects on, 37
Brain-derived neurotrophic factor (BDNF), 89–90
Breathing bag, 177
Breathing pattern, monitoring patient, 219
Breathing systems, 174–183
  nonrebreathing, 180–183, 182f, 184f
  rebreathing (circle system), 175–180
Bronchial alveolar lavage (BAL), hypoxia and, 521
Bronchoscopy, 504–505
Buffer systems
  chemical buffering, 243–245
    bicarbonate buffer system, 243
    factors influencing intracellular, 244–245
    isohydric principle and, 245
    phosphate buffer system, 244
    protein buffer system, 244
  major body, 242t
Bunsen solubility coefficient, 64
Bupivacaine. See also Local anesthetics
  in cesarean section patients, 474t
  chirality, 329
  corneal desensitization, 369
  doses for peripheral and epidural block procedures, 364t
  epidural use, 363–364, 376
  infiltration anesthesia, 369
  metabolism of, 343
  opioids for extending effect, 498
  overdose treatment, 347
  properties, 332t
  topical use, 369
  toxic dose, 498
  trade name, structure, and main uses, 330t
Buprenorphine
  in cesarean section patients, 473t
  in dental patients, 498–499
  for extending effect of local anesthetics, 498
  for injectable postoperative analgesics, 288t
  ocular effects, 467t
  in orthopedic patients, 500
  overview of, 114–115
  preanesthetic use, 282t
  in respiratory disease patients, 393
  in rodents and rabbits, 313t
  in shock, 486
  sublingual administration of, 155
  use in cats, 155
Butacaine, 349
Butorphanol
  in cesarean section patients, 473t
  in GI endoscopy patients, 440
  for injectable postoperative analgesics, 288t
  ocular effects, 467t
  in orthopedic patients, 500
  overview of, 113–114
  preanesthetic use, 282t
  in renal disease patient anesthesia, 418t
  in respiratory disease patients, 393
  for reversal of opioid agonists, 287
  in rodents and rabbits, 313t
  in shock, 486
Butyrophenones, 44
Calcium gluconate
  for hyperkalemia, 455
  for hypocalcemia, 459
Cancer pain
  chronic, 148t
  defined, 83
  NSAIDs for, 123
  WHO “analgesic ladder” for treatment of, 151–152, 151t
CaO2 (arterial oxygen content), 201–203, 213–216, 217t, 218
Capillaries
  lymphatic, 18
  types, 16
Capillary refill time (CRT), assessment of, 204
Capnography
  advantages of, 225
  components of the normal capnograph waveform, 221f
  defined, 221
  for ETCO2 monitoring, 221–225
  in ocular patients, 462
  in small mammals, 307
  variations in the normal capnograph, 222–225, 223f–224f
Capnometer, 221–222
Carbon dioxide absorbents, 179–180, 522
Carbon dioxide absorber, 178–179
Carbon dioxide dissociation curve, 30
Carbon dioxide transport, 30
Carbon monoxide poisoning, 180
Cardiac arrest, 513–520
cardiopulmonary resuscitation (CPR), 514–520, 514f, 515f, 518f, 519f
ABCD protocol, 514–517
algorithm, 519f
drug therapy for, 516–517
external thoracic massage, 514–515, 514f, 515f
internal (open thoracic), 516, 517–518
interposed abdominal compression (IAC), 515
owners wishes concerning, 516
postresuscitation care, 520
simultaneous ventilation-compression (SVC), 515–516
defibrillator use, 517, 518f
effect of, 513
signs of, 513, 513t
types, 513
Cardiac catheterization, for cardiac output measurement, 212
Cardiac contractility, 25, 379
Cardiac contraction, 15–16
Cardiac cycle, 23f
Cardiac massage, 514–516
Cardiac output (CO)
defined, 378
determinants of, 20, 22f, 24
fluid balance assessment and, 267
Frank-Starling relationship, 24
inhalant anesthetic agent effect on, 70
mean arterial blood pressure (MAP) and, 208–209
measurement methods, 212–213
monitoring, 212–213
oxygen delivery (DO₂), 201–202
Cardiac rhythm, monitoring, 207–208, 207f
Cardiogenic shock, 479t, 483
Cardiomyopathy
dilated cardiomyopathy (DCM), 384
hypertrophic cardiomyopathy (HCM), 385
Cardiopulmonary resuscitation (CPR), 514–520, 514f, 515f, 518f, 519f
ABCD protocol, 514–517
acupuncture use for, 140
algorithm, 519f
drug therapy for, 516–517
external thoracic massage, 514–515, 514f, 515f
Cardiovascular disease
anesthesia for patients with, 378–386
dilated cardiomyopathy (DCM), 384
hypertrophic cardiomyopathy (HCM), 385
mitral valve insufficiency, 383–384
overview, 382–383
pharmacology of anesthetic drugs, 379–382
cardiac arrest (See Cardiac arrest)
fluid therapy considerations, 264
Cardiovascular support
in neurological disease patients, 404–405, 404t
for shock, 483–484
inotropes, 483, 484t
vasopressors, 483–484, 485t
in traumatized and critically ill patients, 488
Cardiovascular system
anatomy, 15–25
blood, 18–19, 18f
blood pressure, 20, 21f
blood vessels, 16, 17f, 18
heart, 15–16
anesthetic emergencies, 510–512
assessment in small mammals, 309
disease (See Cardiovascular disease)
inhalation anesthetic agent action and toxicity, 70–71
opioid side effects, 104
pharmacology of anesthetic drugs, 379–382
analgesic drugs, 382
induction drugs, 381–382
maintenance drugs, 382
overview of cardiovascular effects, 380t
sedatives, tranquilizers, and anticholinergics, 379–381
physiology, 15–25, 378–379
afterload, 25
alterations in pregnancy, 470t
cardiac electrophysiology, 20–24, 23f
cardiac output, 20, 22f
Index 537

determinants of performance and output, 24–25
inotropy, 25
lusitropy, 25
nervous, humoral, and local control, 20–21
in ocular patients, 464
preload, 24
pressure, resistance, and flow, 19–20
supporting (See Cardiovascular support)
toxicity of local anesthetics, 344–345
Carprofen
dosage ranges, 126t
for injectable postoperative analgesics, 288t
ocular effects, 467t
for oral postoperative analgesics, 289t
overview of, 126
in rodents and rabbits, 313t
Catheter
for cardiac output measurement, 212–213
for central venous pressure measurement, 211–212
for direct arterial blood pressure measurement, 210–211
epidural, 526–527
for fluid administration, 265–266
for interpleural regional analgesia, 355–357
Causalgia, 83
Central nervous system (CNS). See also Nervous system
inhalation anesthetic agent action and toxicity, 68–69
analgesia, 69
cerebral blood flow, 69
cerebral metabolism, 69
electroencephalographic effects, 69
intracranial pressure (ICP), 69
monitoring function, 198–200
objective methods, 199–200
subjective methods, 198–199
opioid side effects, 103
toxicity of local anesthetics, 344
Central pain, 84
Central venous pressure (CVP)
for fluid balance assessment, 266
mean arterial blood pressure (MAP) and, 208–209
monitoring, 211–212
in renal disease patients, 418
in traumatized and critically ill patients, 488
Cerebral blood flow
autoregulation of, 401–402, 401f
drug effects on, 69, 403–405, 404t
intracranial pressure (ICP) and, 400–402
Cerebral metabolic rate (CMR), 401, 403, 404
Cerebral metabolic requirement for oxygen (CMRO2), 46, 401, 407
Cerebral metabolism, of inhalation anesthetic agents, 69
Cerebral perfusion pressure (CPP), 489
Cerebrospinal fluid (CSF), 37–39, 38f
drug effects on, 403
Cesarean section patients, 469–477
anesthetic drugs in, 472, 473t–474t
care of newborns, 476–477
fetal pharmacokinetics, 472
general anesthesia, 474–475, 475t
general considerations, 469
impact of physiological changes on anesthetic management, 470–471
pain management, 477
physiological alterations induced by pregnancy, 469, 470t
placental transfer of drugs, 471–472
regional anesthesia, 475–476
uterine blood flow during pregnancy, 469–470
Charles’s law, 60
Check valve, 173, 522
Chemical buffer systems, 243–245
Chemoreceptors, 31
Chemoreceptor trigger zone, opioids and, 103
Cheyne-Stokes respirations, 26
Chinchillas, 319
Chirality, of local anesthetics, 329
Chloralose, in laboratory mammals, 303t, 306
Chloride shift, 30
Chloroprocaine. See also Local anesthetics
doses for peripheral and epidural block procedures, 364t
metabolism of, 343
properties, 332t
trade name, structure, and main uses, 331t
Cholinesterase, plasma levels of, 471
Choral hydrate, in laboratory mammals, 303t, 306
Choroid plexus, 37
Chronic pain
assessment of, 96, 98
defined, 84
Circle system, 175–180
coaxial systems, 177
non (minimal)-rebreathing, 175–176
Circulation
key factors relating to, 202f
monitoring, 204–213
objective methods, 205–213
arterial blood pressure, 208–211, 211f
cardiac output, 212–213
cardiac rhythm, 207–208, 207f
central venous pressure, 211–212
heart rate or pulse rate, 205–206
subjective methods, 204–205
capillary refill time (CRT), 204
pulse palpation, 204–205
Cisatracurium
in liver disease patients, 427
pharmacology, 79
in portosystemic shunt patients, 430
Closing volume, lung, 521–522
CMR. See Cerebral metabolic rate (CMR)
CMR (cerebral metabolic rate), 401, 403, 404
CMRO₂ (cerebral metabolic requirement for oxygen), 46, 401, 407
CNS. See Central nervous system (CNS)
CO. See Cardiac output (CO)
Coagulation profile, 423
Cocaine
metabolism of, 343
topical use, 349
trade name, structure, and main uses, 331t
Codeine
acetaminophen combined with, 111
dosage ranges, 106t
for oral postoperative analgesics, 289t
overview of, 111
Cold, therapeutic, 141–142
Cole endotracheal tube, 160, 162, 162f
Colloidal osmotic pressure (COP)
defined, 259
measurement of, 267
serial evaluation of, 226
Colloid osmometry, 267
Colloids, 270–271
for blood/fluid loss during surgery, 511
composition and properties of, 272t
synthetic, 271
Combination analgesics, for chronic pain, 156
Common gas outlet, anesthetic machine, 174
Compliance of breathing system, 194
Compound A, 72, 179–180, 415
Computed tomography (CT), 506
Concentration of weak acids (ATOT), 255
Conjunctival sac, local anesthetic instillation into, 349
Constipation, from opioid use, 104
Contrast agents, 506
Co-oximetry, for hemoglobin saturation measurement, 217
COP. See Colloidal osmotic pressure (COP)
Copenhagen approach, to acid-base balance, 251
Corneal ulcers, during anesthesia, 526
Corticosteroids. See also specific drugs
NSAID concurrent use, 124
for postsurgery airway obstruction, 395
Cortisol
depletion in adrenal insufficiency, 456
as pain marker, 93
Cough reflex, opioids and, 103
COX. See Cyclooxygenase (COX) enzymes
Coyru, 320
CPP (cerebral perfusion pressure), 489
CPR. See Cardiopulmonary resuscitation (CPR)
Cranial nerves, 35, 36f
Critically ill patients, 477–490
anesthetic management, 486–490
anesthetic induction, 487
anesthetic maintenance, 488
fluid therapy and cardiovascular support, 488
mechanical ventilation, 489
patient monitoring, 488
preanesthetic period, 486–487
recovery, 490
regional anesthesia, 489–490
general considerations, 477–478
shock, 478–486
Cross fiber massage, 143
CRT (capillary refill time), assessment of, 204
Cryotherapy, 141–142
Crystalloids, 268–270
  for blood/fluid loss during surgery, 511
  composition of, 269t
  free water solutions, 270
  hypertonic solutions, 270
  maintenance solutions, 268, 270
  replacement solutions, 268
C-section. See Cesarean section patients
CSF. See Cerebrospinal fluid (CSF)
CT (computed tomography), 506
Cuff monitor, 163
Cushing’s disease, 456
CVP. See Central venous pressure (CVP)
Cyclooxygenase (COX) enzymes
cyclooxygenase-1 (COX-1), 116–121, 123–
  124, 126–128, 152

cyclooxygenase-2 (COX-2), 116–121, 124,
  126–127, 152

cyclooxygenase-3 (COX-3), 116–120, 127,
  128, 154
NSAID inhibition of, 116–121, 123–124,
  126–128
prostaglandin synthesis and, 116–118, 117f
Dalton’s Law of Partial Pressure, 60
DCM (dilated cardiomyopathy), 384
Dead space volume (Vd), 218, 387–388
Deafferentation pain, 84
Deep peroneal nerve block, 373f
Defecation, opioid use and, 104
Defibrillator, 517, 518f
Dehydration, perianesthetic fluid therapy for,
  264
Delayed recovery, 522, 524
Delta (θ) receptor
  antinociception, 136–137
  described, 99–102
Density, 60
Dental pain
  chronic pain and, 148t
  NSAIDs for, 123
Dental patients, 496–499
  anesthetic management, 497
  general considerations, 496
  pain management, perioperative, 497–499
  dispensable medications, 498–499
    local and regional anesthesia, 497–498
Depth of anesthesia. See Anesthetic depth
De-Qi sensation, 134–135, 136
Deracoxib
  dosage ranges, 126t
  in liver disease patients, 425–426
  ocular effects, 467t
  for oral postoperative analgesics,
    289t
  overview of, 126–127
Dermatome, 84
Desflurane
  biotransformation of, 66
  cardiovascular effects, 70
  in cesarean section patients, 474t
  electroencephalographic effects, 69
  for exploratory laparotomy, 443
  hepatic effects, 72
  in liver disease patients, 427
  physical and chemical characteristics, 58t,
    59t, 62
  renal effects, 415
  respiratory effects, 392
  vaporizer for, 173
Desmopressin, 458
Dexamethasone
  ophthalmic indications and side effects,
    465t
  use in newborns, 476
Dexmedetomidine
  analgesia, 129
  cardiovascular effects, 380t, 381
  in cesarean section patients, 473t
  described, 45
  in intramuscular anesthetic protocol in cats,
    285t
  in intramuscular anesthetic protocol in
dogs, 284t
  in laboratory mammals, 302
  in liver disease patients, 424–425
  in neonatal and geriatric patients, 494
  in neurological disease patients, 403
  ocular effects, 466t
  in orthopedic patients, 500
  preanesthetic use, 279, 282t
  renal effects, 414
  respiratory effects, 391
Dextromethorphan, for chronic pain,
  155
Dextrose, for hyperkalemia, 455
Diabetes insipidus, 457–458
Diabetes mellitus, 457
Diagnostic and therapeutic procedures, 504–508. See also specific procedures
bone marrow aspiration, 505
bronchoscopy, 504–505
computed tomography (CT), 506
esophagostomy tube placement, 505
general considerations, 504
laryngoscopy, 504
magnetic resonance imaging (MRI), 506–508, 508t
radiation therapy, 508
thoracic drain placement, 505
ultrasonography, 508
Diameter index safety system (DISS), 167
Diazepam
cardiovascular effects, 380–381, 380t
in cesarean section patients, 473t
described, 48–49
for exploratory laparotomy, 443
ocular effects, 467t
in respiratory disease patients, 393–394
use with ketamine in cats, 56
Diclofenac, 120
Diencephalon, 35
Diffusion impairment, hypoxemia from, 388, 389t
Dilated cardiomyopathy (DCM), 384
Diltiazem
intravenous dose for heart rate/rhythm abnormalities, 228t
for tachyarrhythmias, 231
Dipivefrine, 465t
Dipyrone
COX-3 inhibition, 120
overview of, 128
DISS (diameter index safety system), 167
Dissociative anesthetics. See also specific drugs
analgesia from, 55
clinical usage
in cats, 56–57
in dogs, 56
in liver disease patients, 426
pharmacology, 55–57
respiratory effects, 391
Distress, 4, 84
Distribution, of local anesthetics, 342
Diuretics, for elevated intracranial pressure, 402
DO2. See Oxygen delivery (DO2)
Dobutamine
for cardiovascular support, 484t
in portosystemic shunt patients, 430
Dopamine
for cardiovascular support, 484t
perivascular injection, 520
in portosystemic shunt patients, 430
renal effects, 419
Dopexamine, for cardiovascular support, 484t
Doppler system
for arterial blood pressure (ABP) measurement, 210
for pulse rate monitoring, 206
Doppler ultrasonography, for cardiac output estimation, 213
Dorsal horn, pain modulation in, 89–91
Doxacurium, 80
Doxapram, use in newborns, 477
Drip rate, 266
Driving gas, control of ventilator, 192–193
Drug deposition, of local anesthetics, 339–343, 340f
Drug interactions, 7–8
common with anesthetic drugs, 8–9
nomenclature, 8
opioid drug interactions, 9
in vitro versus in vivo, 7–8
Drug protocol selection, for anesthesia, 274, 278–279
Drugs. See also specific drugs
nomenclature, 8
selection of an anesthetic and analgesic, 7–9
Drug selection
patient-related factors, 288–293
procedure-related factors, 293–298
by length of procedure, 296–298
by level of invasiveness, 293–296
D5W (five percent dextrose in water), 270
Dynamic and interactive visual analog scale (DIVAS), 94–95
Dynorphins, 100, 101
Dysesthesia
defined, 84
neuropathic pain and, 91
Dyspnea, 26
Dysrhythmia, as anesthetic emergency, 511–512
Index

541

ECF compartment, 258
ECG. See Electrocardiogram (ECG)
Echthiophate, 465t
ED50 (median effective dose), 67, 68
ED95 (effective dose 95%), 67, 68
Edema
  pulmonary, 395
  upper airway, 395
Edrophonium, 81
EEG. See Electroencephalography (EEG)
Effective osmole, 259
Effective SID (SIDeff), 255–256
Effleurage, 143
Eicosanoid synthesis, 117f
Electrical mechanical dissociation, 513
Electrical stimulation
  of acupuncture points, 136–137, 139
  rehabilitation therapy, 145–146
Electroacupuncture, 136–137, 139
Electrocardiogram (ECG)
  components of the normal waveform, 207f
  esophageal electrodes, 208
  in gastric dilatation-volvulus (GDV), 445
  handheld units, 208
  for heart rate monitoring, 206
  in hyperkalemia, 416
  lead placement, 207
Electrodes, ECG, 207–208
Electrodiagnostic techniques, anesthetic management and, 407
Electroencephalography (EEG)
  anesthetic depth and, 199–200
  anesthetic management during, 407–408
  inhalation anesthetic agents effects, 69
Electrolytes. See also Fluid therapy
  defined, 258
  distribution, 259, 259t
  imbalance in renal disease, 416–417
Electrophysiology, 326–327
Electoretinography (ERG), 468
Elimination
  Hofmann, 78, 79
  of inhalation anesthetic agents, 65, 66f
  of neuromuscular blocking agents, 78, 79
Elizabethan collars, 463
Emergencies. See Anesthetic emergencies
Emesis, opioids and, 103
EMLA Cream, 341, 369
Endocrine disorders
  adrenal gland, 455–456
    adrenal insufficiency, 455–456
    hyperadrenocorticism, 456
    pheochromocytoma, 456
  fluid therapy considerations with, 265
  pancreas, 457–458
    diabetes insipidus, 457–458
    diabetes mellitus, 457
    insulinoma, 458
  parathyroid gland, 458–459
  thyroid gland, 459–460
Endoscopy
  anesthetic concerns/complications, 436t
  gastrointestinal, 436t, 437–441, 438f
Endotracheal tube, 160–163
  for airway during resuscitation, 514
  characteristics of, 161f
  Cole-type, 160, 162, 162f
  cuff inflation pressure, monitoring, 227
  in GI endoscopy patients, 439
  inflation guide/monitor, 163, 164f
  kinking and obstruction, 522, 523f
  local anesthetic use with, 349–350
  Magill-type, 163
  materials, 160
  Murphy-type, 160, 161f
  placement
    in small mammals, 307–308, 308f
    in upper airway dysfunction patients, 394–395
  sizes, 160
  wire-reinforced, 462, 522, 523f
End-tidal CO2 tension (ETCO2), 237–238
  factors increasing the gradient between arterial and end-tidal CO2, 224t
  measurement with capnometer, 221–222
  monitoring, 221–225
  as PaCO2 surrogate, 221
  in renal disease patients, 418
  in traumatized and critically ill patients, 489
End-tidal inhalant anesthetic concentration (ETagent), 198
Enflurane
  biotransformation of, 71
  in liver disease patients, 427
  physical and chemical characteristics, 58t, 59t
Enkephalins, 100, 101
EP (evoked potential), anesthetic depth and, 200
Ephedrine, for cardiovascular support, 484t
Epidural anesthesia/analgesia
for cesarean section, 476
complications, 526–527
continuous, 362–363
differential blockade, 335
disadvantages of, 476
fentanyl, 110
lumbosacral in cats, 374–376, 375f
lumbosacral in dogs, 360–368, 361f, 364t, 365t
adverse effects, 367–368
continuous epidural anesthesia, 362–363
epidural nonopioid analgesia, 366–367
epidural opioid analgesia, 365–366
local anesthetic choice, 363, 365
local anesthetic doses, 364t
needle placement, 360–361, 361f
opioid properties, 365t
procedure, 360–362, 361f
opioid, 365–366, 490
in traumatized and critically ill patients, 489–490
Epidural space, 37
Epinephrine
for anaphylaxis, 512–513
for cardiopulmonary resuscitation (CPR), 516, 518
for cardiovascular support, 485t
intracardiac injection, 516, 518
as local anesthetic additive, 336–337
for myocardial failure, 347
ophthalmic indications and side effects, 465t
Equipment. See Anesthesia equipment
ERG (electroretinography), 468
ERV (expiratory reserve volume), 26
Esmolol
intravenous dose for heart rate/rhythm abnormalities, 228t
for tachyarrhythmias, 231
Esophageal pH, measuring, 227
Esophageal stethoscope, for heart rate monitoring, 206
Esophagostomy tube placement, 505
Ester hydrolysis, of neuromuscular blocking agents, 79, 80
Eye
  eyeball position as anesthetic depth indicator, 199
  nerve block in dogs, 353–354

Face
  nerve block in cats, 369, 370f
  nerve block in dogs, 352–353, 352f
Face mask, for anesthesia induction in small mammals, 301
Fasting, preanesthetic, 5
Feet, swollen, 526
Fencl-Stewart approach to acid-base analysis, 256
Fenoldopam, renal effects of, 419
Fentanyl
  adverse effects, 110
  for analgesia in maintenance phase of anesthesia, 296t
  analogs of, 111
  for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
  in cesarean section patients, 473t
  clinical uses, 110
  dosage ranges, 106t
  for epidural use, 110, 365t, 376
  for induction in patients with trauma and/or hemodynamic instability, 292t
  for injectable postoperative analgesics, 288t
  ocular effects, 467t
  overview of, 109–110
  pharmacology, 109–110
  in respiratory disease patients, 392, 395
  in shock, 486
  transdermal patches, 110
Fentanyl-droperidol (Innovar-Vet), in rodents and rabbits, 316t
Fentanyl-fluaniponge
  in laboratory mammals, 303t–304t, 305
  in rodents and rabbits, 316t
Fentanyl-fluaniponge-midazolam, in laboratory mammals, 303t–304t, 305
Ferrets, 322
Fetal pharmacokinetics, 472
Fever
  cyclooxygenase enzymes and, 120
  inhibition by NSAIDs, 120
FGF. See Fresh gas flow (FGF)
FiCO₂ (inspired concentration of oxygen), 215–217
Field block, 351, 352f
Filler port, vaporizer, 173
FIO₂ (fraction of inspired oxygen), 234, 388, 389t
Firocoxib
  dosage ranges, 126t
  ocular effects, 467t
  for oral postoperative analgesics, 289t
  overview of, 126–127
First-degree AV block, 229, 229f
Five freedoms for evaluation of animal welfare, 149, 149t
Five percent dextrose in water (D₅W), 270
Flow meter, 169
Flow rate, through the vaporizer, 172
Fluid administration sets, 266
Fluid balance, assessing, 266–267
Fluid loss, as anesthetic emergency, 510–511
Fluid pumps, 266
Fluid therapy
  administration sets for, 266
  for blood/fluid loss during surgery, 511
  catheters for, 265–266
  distribution of fluid and electrolytes, 259–260, 259t
  fluid types, 268–273
  blood products, 271, 273
  plasma, 271
  PRBCs, 273
  whole blood, 273
  colloids, 270–271
  composition and properties of, 272t
  synthetic, 271
  crystalloids, 268–270
  composition of, 269t
  free water solutions, 270
  hypertonic solutions, 270
  maintenance solutions, 268, 270
  replacement solutions, 268
  gastric dilatation-volvulus (GDV), 444–445
  hemoabdomen, 446
  for hemorrhage, 481
  maintenance volume, calculating, 270
  in obese patients, 451
  options for volume resuscitation in hypovolemic shock, 482t
Fluid therapy (cont’d)
perianesthetic, considerations for
delivery and administration
considerations, 265–266
fluid balance, assessing, 266–267
patient status, 260–265
anemia, 261
cardiovascular disease, 264
dehydration, 264
endocrine disease, 265
hemostatic disorders, 265
hypercalcemia, 263
hyperglycemia, 264
hyperkalemia, 262–263
hypernatremia, 262
hypocalcemia, 263
hypoglycemia, 263
hypokalemia, 262–263
hypoproteinemia, 261
hypovolemia, 260
metabolic acid-base disorders, 264
preexisting disease states, 264–265
renal disease, 265
response to therapy, monitoring, 266–267
preanesthetic, 5–6
regulation of fluid balance, 258–260
in renal disease patients, 417–418, 418f
in small mammals, 310, 311t
terminology, 258–259
in traumatized and critically ill patients, 488
Flumazenil
for benzodiazepine reversal, 286, 391
described, 50
in hepatic encephalopathy patients, 429
Flunixin meglumine
dosage ranges, 126t
ocular effects, 467t
in rodents and rabbits, 313t
Fluoride, and nephrotoxicity of inhalant
anesthetics, 71–72
Foot, nerve block in dogs, 357–360
Force plate gait analyses, 93–94
Fraction of inspired oxygen (FIO2), 234, 388, 389t
Frank-Starling relationship, 24
FRC. See Functional residual capacity (FRC)
Free water solutions, 270
Fresh gas flow (FGF)
flow meter control of, 169
tidal volume, effect on, 193–194
Fresh gas inlet, 176
Frick equation, 19
Functional hemoglobin saturation (SpO2),
217–218, 219
Functional residual capacity (FRC)
decreased during anesthesia, 521–522
defined, 27
in obese patients, 451
in pregnant patients, 471
Furosemide, in renal disease patients, 419
Gamma-aminobutyric acid (GABA)
Gabapentin
analgesia, 129–130
for chronic pain, 156
dosage ranges, 129t
for oral postoperative analgesics, 289t
Gag reflex, as anesthetic depth indicator, 199
Gamma-aminobutyric acid (GABA)
barbiturates and, 51
benzodiazepines and, 48
decrease in neuropathic pain, 92
etomidate and, 53
opioid signaling and, 101
Gas anesthetic agents. See Inhalant anesthetic
agents
Gas cylinders, 166, 166t
Gas supply. See Medical gas supply
Gastric dilatation-volvulus (GDV), 444–446
Gastroaesophageal reflux (GER)
during anesthesia, 524
exploratory laparotomy and, 442
megaeosophagus and, 437
monitoring, 226–227
Gastrointestinal disease, 434–452
anesthetic concerns/complications, 436t
endoscopy, 436t, 437–441, 438f
exploratory laparotomy, 441–444
anesthetic concerns/complications, 436t
anesthetic protocol for, 443–444
gastric dilatation-volvulus (GDV), 444–446
hemoabdomen, 446–447
megaeosophagus, 436–437, 436t
oral and pharyngeal conditions, 434–436,
435f, 436t
Gastrointestinal system
disease (See Gastrointestinal disease)
NSAIDs adverse effects on, 119, 121, 123, 152
opioid side effects, 104
physiology alterations in pregnancy, 470t
Gay-Lussac’s law, 60
GDV (gastric dilatation-volvulus), 444–446
General considerations, 504
Genitourinary system, opioid side effects on, 104–105
GER. See Gastroesophageal reflux (GER)
Gerbils. See also Laboratory mammal anesthesia
anesthetic drugs for use in, 304t
fluid volumes for administration, 311t
physiological data for, 301f
Geriatric patients
anesthetic drug selection for, 290
anesthetic induction, 494–495
anesthetic maintenance, 495
general considerations, 490
patient evaluation and preparation, 491–493
physiology, 490–491, 492t
preanesthetic period, 493–494
supportive care, 495–496
GFR. See Glomerular filtration rate (GFR)
Glasgow Composite Measures Pain Scale, 95–96, 97f
Globe motion, during anesthesia, 463
Glomerular filtration rate (GFR)
anesthetics effect on, 414–415, 414t, 417
in chronic renal failure, 413
dopamine for promotion of, 419
increase with
dopamine, 419
fenoldopam, 419
Glucocorticoids
for cerebral edema, 402
for epidural, 367
Glucose homeostasis, liver role in, 423
Glutamate receptor, 89, 92
Glycerin, 465t
Glycopyrrolate
for cardiopulmonary resuscitation (CPR), 517
in cesarean section patients, 473t
clinical uses, 43
dysrhythmias from, 512
intravenous dose for heart rate/rhythm abnormalities, 228t
ocular effects, 466t
in orthopedic patients, 500
pharmacokinetics and pharmacodynamics, 43
preanesthetic use, 279–280, 282t
in respiratory disease patients, 396
in rodents and rabbits, 315, 316t
structure, 43
Greyhounds, thiobarbiturates and, 291
Guinea pig. See also Laboratory mammal anesthesia
anesthetic drugs for use in, 302, 304t, 305
fluid volumes for administration, 311t
physiological data for, 301f
Haldane effect, 244
Halothane
cardiac output depression, 70
hepatic effects, 72
in liver disease patients, 427
in obese patients, 451
physical and chemical characteristics, 58t, 59t
Hamster. See also Laboratory mammal anesthesia
anesthetic drugs for use in, 304t
fluid volumes for administration, 311t
physiological data for, 301f
Heart, anatomy and physiology of, 15–16
Heart rate
anesthetic complications, 228–231
as anesthetic depth indicator, 198–199
assessment in small mammals, 309
cardiac output and, 378–379
drugs used to manage abnormalities of, 228t
inhalant anesthetic agent effect on, 70
monitoring, 205–206
in neonatal patients, 496
in ocular patients, 462
Heart rhythm
anesthetic complications, 228–231
drugs used to manage abnormalities of, 228t
Heat therapy, 142
Hedgehogs, 324–325
Hemoabdomen, 446–447
Hemodynamically unstable patients, anesthetic drug selection for, 292, 292t, 293t
Hemoglobin
  oxygen bound to (SaO₂), 201–203, 214–218, 217t
  oxygen transport, 18–19
  oxyhemoglobin dissociation curve, 18f
  in protein buffer system, 244
Hemoglobin-based oxygen-carrying solutions, 511
Hemorrhage
  anesthetic emergency, 510–511
  assessment of magnitude of, 481t
  hemoabdomen, 446–447
Hemorrhagic shock, 480–481, 481t
Hemostatic disorders, fluid therapy considerations with, 265
Henderson-Hasselbach equation, 241
Henry’s law, 63
Hepatic blood flow, 422
Hepatic encephalopathy, 424, 429
Hepatic system. See Liver
Hepatocellular enzyme concentrations, 423
Hepatorenal physiology, alterations in pregnancy, 470t
Histamine, opioid-caused release of, 104
HOD (hypertrophic osteodystrophy), NSAIDs for, 123–124
Hofmann elimination, 78, 79
Housing, ventilator, 191
Hyaluronidase, as local anesthetic additive, 337
Hydromorphone
  dosage ranges, 106t
  overview of, 111–112
Hydrocortisone acetate, ophthalmic indications and side effects of, 465t
Hydrogen ion (H⁺), 241
Hydromorphone
  for analgesia in maintenance phase of anesthesia, 296t
  in cesarean section patients, 473t
  dosage ranges, 106t
  for induction in patients with trauma and/or hemodynamic instability, 292t
  for injectable postoperative analgesics, 288t
  ocular effects, 467t
  overview of, 108
  preanesthetic use, 282t
in renal disease patient anesthesia, 418t
respiration depression from, 521
in respiratory disease patients, 392
in shock, 486
Hyperadrenocorticism, 456
Hyperalgesia
  assessment of, 93
  defined, 84
  neuropathic pain and, 91
Hypercalcemia, perianesthetic fluid therapy for, 263
Hypercapnia
  effect of, 219
  from hypoventilation, 388
  managing anesthetic complications, 237–238
  secondary to hypoventilation, 237–238
Hyperesthesia, 84
Hyperglycemia, perianesthetic fluid therapy for, 264
Hyperkalemia
  in adrenal insufficiency, 455
  ECG abnormalities in, 416
  perianesthetic fluid therapy for, 262–263
  in renal disease, 416–417, 419–420
Hypernatremia, perianesthetic fluid therapy for, 262
Hyperparathyroidism, 458
Hyperpnea, 26
Hypertension
  managing anesthetic complications, 233–234
  with pheochromocytoma, 456
Hyperthermia
  accidental iatrogenic, 526
  drug-induced, 525–526
  local, 142
  malignant, 525–526
  managing anesthetic complications, 239
Hyperthyroidism, 459–460
Hypertonic fluid loss, 259
Hypertonic saline solutions, 270
Hypertrophic cardiomyopathy (HCM), 385
Hypertrophic osteodystrophy (HOD), NSAIDs for, 123–124
Hyperventilation
  hypercapnia and, 237
  managing anesthetic complications, 238
  to reduce cerebral blood flow, 402
Index 547

Hypnotics, effect on control of ventilation, 32–33

Hypoadrenocorticism, 455–456

Hypoalbuminemia
  effect on anion gap calculation, 253
  in liver disease, 423
  perianesthetic fluid therapy for, 261

Hypocalcemia, 263, 458–459

Hypocapnia
  managing anesthetic complications, 238
  secondary to iatrogenic hyperventilation, 238
  side effects of, 238

Hypoesthesia, 84

Hypoglycemia
  in liver disease, 423
  perianesthetic fluid therapy for, 263

Hypokalemia, perianesthetic fluid therapy for, 262

Hyponatremia, perianesthetic fluid therapy for, 261–262

Hypoparathyroidism, 458–459

Hypopnea, 26

Hypoproteinemia, perianesthetic fluid therapy for, 261

Hypotension
  drugs used to manage, 233t
  managing anesthetic complications, 231–233

Hypothalamus, nociceptive information and, 86

Hypothermia
  during anesthesia, 525
  as anesthetic technique in neonatal rodents, 314–315
  in dental patients, 497
  local, 141–142
  managing anesthetic complications, 238–239
  in neonatal and geriatric patients, 495
  opioids and, 103
  in small mammals, 309
  therapeutic after cardiopulmonary resuscitation (CPR), 520
  in traumatized and critically ill patients, 489

Hypothyroidism, 459

Hypotonic fluid loss, 259

Hypovolemia, perianesthetic fluid therapy for, 260

Hypovolemic shock, 479t, 482t

Hypoxemia
  causes, contributing factors, and response to oxygen supplementation, 389t
  causes in anesthetized dogs and cats, 235t
  defined, 28
  from hypoventilation, 388, 389t
  managing anesthetic complications, 234–237, 235t
  mechanisms of, 234
  in pregnant patients, 471
  severity, calculation of, 390t

Hypoxia
  after bronchial alveolar lavage (BAL), 521
  defined, 28
  during recovery from anesthesia, 521

IAC (interposed abdominal compression), 515

Ibuprofen, 120

IC (inspiratory capacity), 27

ICF compartment, 258

ICP. See Intracranial pressure (ICP)

Ileus, from opioid use, 104

Induction of anesthesia, 280–281, 283–284
  in cats, 287t
  in dogs, 286t
  goals of, 283b
  inhalant agents, 281
  intramuscular agents, 283, 284t, 285t
  intravenous agents, 283–284, 286t
  in neonatal and geriatric patients, 494–495
  in orthopedic patients, 500–501
  in renal disease patients, 418t
  in respiratory disease patients, 391
  lower airway dysfunction, 397
  upper airway dysfunction, 394
  in traumatized and critically ill patients, 487

Ineffective osmole, 259
Inferior alveolar nerve, desensitization of, 369, 370, 370f, 498

Infiltration anesthesia
  brachial plexus, 332, 334, 334f
  in cats, 369
  continuous, 351
  in dental patients, 498
  in dogs, 350–351

Inflammatory pain, 84

Infraorbital nerve, desensitization of
  in cats, 369–370, 370f
  in dogs, 352–353, 352f

Inhalant anesthetic agents. See also specific drugs
  action and toxicity, 68–75
  cardiovascular system, 70–71
  CNS, 68–69
  analgesia, 69
  cerebral blood flow, 69
  cerebral metabolism, 69
  electroencephalographic effects, 69
  intracranial pressure (ICP), 69
  hepatic system, 72
  nitrous oxide-specific, 73–75
  renal system, 71–72
  respiratory system, 70
  skeletal muscle, 73
  cardiovascular effects, 380t, 382
  for exploratory laparotomy, 443
  induction with, 281
  in neonatal and geriatric patients, 494–495
  in neurological disease patients, 404
  in obese patients, 451
  occupational exposure, 75
  in orthopedic patients, 501
  pharmacology, 57–75
    biotransformation, 65–66
    calculation of anesthetic concentration delivered by vaporizer, 62, 63f
    chemical characteristics, 57, 58t
    MAC (minimum alveolar concentration), 67–68
    partition coefficient (PC), 59t, 64
    physical characteristics, 58t, 59–64, 59t
    properties determining methods of administration, 59–62
    properties influencing drug kinetics, 62–64
  quantities of agent, 60
  uptake and elimination, 64–66, 66f
  renal effects, 414t, 415
  in respiratory disease patients, 397
  respiratory effects, 392

Injectable anesthetic agents. See also specific drugs
  IM induction, 283, 284t, 285t
  IV induction, 283, 286t
  in laboratory mammals, 302–306, 303t–304t
  in neurological disease patients, 403
  in orthopedic patients, 500
  pharmacology, 50–57
    barbiturates, 51–52
    dissociative anesthetics, 55–57
    etomidate, 53–54
    neurosteroids, 52–53
    propofol, 54
    renal effects, 414t, 415

Inotropes, for shock, 483, 484t

Inotropy, 25

Insectivora, 324–325

Inspiration capacity (IC), 27

Inspiratory one-way valve, 176

Inspiratory reserve volume (IRV), 26

Inspired concentration of oxygen (FiCO2), 215–217

Insulin
  for diabetes mellitus, 457
  excessive in insulinoma, 458

Insulinoma, 455, 458

Insurance claims, 12, 12t, 14

Intercostal nerve block
  in cats, 373–374, 374f
  in dogs, 354–355, 355f

Intermittent positive-pressure ventilation (IPPV)
  for hypoxia after functional residual capacity (FRC) changes, 522
  in laparoscopy for liver biopsy/excision, 428–429
  in lower airway disease patients, 397

Interpleural regional analgesia, 355–357

Interposed abdominal compression (IAC), 515

Interstitial fluid compartment, 258

Interventional radiology, for portosystemic shunts, 429–430
Intervertebral disc disease, anesthetic management in, 405–406
Intestinal function, acupuncture and, 140
Intra-articular analgesia, 357
Intracardiac injection, of epinephrine, 516
Intracranial masses, 406
Intracranial pressure (ICP)
anesthetic management and, 406
cerebral blood flow effect on, 400–402
described, 489
drug effects on, 39, 69, 404t
mannitol for reducing, 406
Intracranial pressure (IOP), 461, 462, 468
Intravascular fluid (plasma) compartment, 258
Intubation, 394–395. See also Endotracheal tube
Ionophoresis, 340, 341
IPPV. See Intermittent positive-pressure ventilation (IPPV)
IRV (inspiratory reserve volume), 26
Isofluorophate, ophthalmic indications and side effects of, 465t
Isoflurane
for anesthesia induction, 286t
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
apnea and, 521
cardiovascular effects, 70, 380t
in cesarean section patients, 474t
electroencephalographic effects, 69
for exploratory laparotomy, 443
in GI endoscopy patients, 440
hepatic effects, 72
hypotension and, 231
in liver disease patients, 427
in obese patients, 451
ocular effects, 466t
physical and chemical characteristics, 58t, 59t
in renal disease patient anesthesia, 418t
renal effects, 414t, 415
respiratory effects, 392
volume calculations, 61f
Isohydric principle, 245
Isotonic fluid loss, 259
IVRA
in cats, 372–373
in dogs, 359–360
Joint pain, following anesthesia, 526
Kappa (κ) receptor, 99–102
agonists, 112
antagonists, 115–116
antinociception, 136–137
Ketamine
analgesia, 129
for analgesia in maintenance phase of anesthesia, 296t
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
apnea and, 521
cardiovascular effects, 380t, 381
in cesarean section patients, 473t
for chronic pain, 155
clinical usage in cats, 56
clinical usage in dogs, 56
dosage ranges, 129t
dysrhythmias from, 512
for epidural use, 367
for exploratory laparotomy, 443
in GI endoscopy patients, 440
for induction in patients with trauma and/or hemodynamic instability, 292t
in intramuscular anesthetic protocol in cats, 285t
in intramuscular anesthetic protocol in dogs, 284t
in laboratory mammals, 302, 303t–304t
in liver disease patients, 426
muscle hypertonus and, 198
in neonatal and geriatric patients, 494
in neurological disease patients, 403
ocular effects, 466t
in orthopedic patients, 500
palpebral reflex and, 199
pharmacology, 55–56
renal effects, 414t, 415
in respiratory disease patients, 397
respiratory effects, 391
use with diazepam in cats, 56
Ketoprofen
as antipyretic agent, 120
dosage ranges, 126t
overview of, 126
Ketorolac
dosage ranges, 126t
overview of, 127
Kidney. See Renal system
Kussmaul’s respirations, 26

Laboratory mammal anesthesia
anesthetic delivery systems, 301
drugs, table of, 303t–304t
general considerations, 300–301
injectable agents, 302–306, 303t–304t
monitoring and intraoperative care,
306–314
emergencies, 310
fluid volumes, 311t
pain alleviation, 312–314, 313t
pain assessment, 311–312
postoperative care, 310–311
respiratory function assessment, 306–309, 308f
thermoregulation, 309
physiological data, 301t
of rodents and rabbits, 315–319
ergils, 317
guinea pigs, 317
hamsters, 317
IP (intraperitoneal) injection, 315, 317f
mice, 318
neonatal rodents, 314–315
overview, 315, 317
preanesthetic agents, 316t
rabbits, 318–319
rats, 318
routes of injection, 318t
Laboratory values, for monitoring anesthesia,
226

Lacrimal nerve, desensitization of, 352f, 353
Lactate, serial evaluations of, 226
Laparoscopy, for liver biopsy/excision, 429
Laparotomy
exploratory for gastrointestinal disease,
441–444
anesthetic concerns/complications, 436t
anesthetic protocol for, 443–444
liver biopsy/excision, 429
portosystemic shunts, 430
Laplace’s law, 19, 25
Laryngeal mask, 160, 308

Laryngoscopes, 163–165
MacIntosh blade, 164, 165, 165f
Miller blade, 164, 165, 165f

Laryngoscopy, 504
Laryngospasm, 394
Lateral plantar nerve block, 373f

Levobupivacaine. See also Local anesthetics
chirality, 329
properties, 332t
trade name, structure, and main uses, 330t

LiDCO system, 212–213

Lidocaine. See also Local anesthetics
after perivascular thiopental injection, 520
for analgesia in maintenance phase of anesthesia, 296t
for anesthesia co-induction, 286t
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
for arrhythmias/dysrhythmias, 447, 486t, 512, 517
in cesarean section patients, 474t
doses for peripheral and epidural block procedures, 364t
epidural use, 363–364, 376
for induction in patients with trauma and/or hemodynamic instability, 292t
infiltration anesthesia, 350–351, 369
intravenous dose for heart rate/rhythm abnormalities, 228t
metabolism of, 343
ocular effects, 467t
opioids for extending effect, 498
properties, 332t
for tachyarrhythmias, 230
topical use, 349, 350, 368–369
toxic dose, 498
trade name, structure, and main uses, 330t

Limb nerve block
in cats, 371
in dogs, 357–360

Lingual nerve, avoiding, 498

Liposyn, 347
Lipoxins, 120–121
5-lipoxygenase (5-LOX), 116, 118, 120
Liver
anatomy and physiology, 422–423
anesthesia for specific procedures, 427–430
liver biopsy/excision, 427–429
laparoscopy, 429
laparotomy, 429
ultrasound-guided, 428
portosystemic shunts, 429–430
interventional radiology, 429–430
laparotomy, 430
biopsy/excision, anesthesia for, 427–429
laparoscopy, 429–430
laparotomy, 429
ultrasound-guided, 428
drug effects, 424–427
analgesics, 425–426
inhalants, 427
injectable anesthetics, 426
neuromuscular blocking agents (NMBAs), 427
sedatives, 424–425
inhalation anesthetic agent action and toxicity, 72
primary functions of, 422
toxicity with NSAIDs, 152
Local anesthetics, 326–377. See also specific drugs
chemical structure, 328–329
chemical grouping, 329
chirality, 329
in dental patients, 487–498
differential nerve blockade, 329–335
brachial plexus infiltration, 332, 334, 334f
classification of nerve fibers and order of blockade, 333t
epidural and spinal blockade, 335
in situ studies, 332
somatosensory arrangement of nerve fibers, 334t
drug deposition, 339–343, 340f
absorption, 340–341
biotransformation and excretion, 342–343
distribution, 342
efﬁcacy, factors inﬂuencing, 335–339
additives, 336–337
baricity, 338
concentration of anesthetic, 336
dose of anesthetic, 335
hyaluronidase addition, 337
injection site, 336
pH adjustment and carbonation, 337–338
pregnancy, 339
temperature, 338–339
vasoconstrictor addition, 336–337
volume of anesthetic, 335–336
electrophysiology, 326–327
local and regional analgesic techniques for cats, 368–377
inﬁltration anesthesia, 369
regional nerve blocks, 369–377
topical anesthesia, 368–369
local and regional analgesic techniques for dogs, 348–368
continuous-inﬁltration anesthesia, 351
ﬁeld block, 351, 352f
inﬁltration anesthesia, 350–351
regional nerve blocks, 351–368
topical anesthesia, 349–350
mechanisms of action, 327–328, 327f
antimicrobial activity, 328
frequency-dependent block, 328
in ocular patients, 465, 468
in orthopedic patients, 501
physical, chemical, and biological properties, 332t
in respiratory disease patients, 392
sprays, 349–350, 368–369
table of agents, 330f–331f
tachyphylaxis, 348
for thoracic surgery patients, 398
toxicity, 343–348
after ingestion, 345
after topical application, 345
allergic reactions, 346–347
cardiovascular, 344–345
CNS, 344
local, 345–346
methemoglobinemia, 346
myotoxicity, 345–346
neurotoxicity, 345
treatment of adverse reactions, 347–348
Low driving gas pressure alarm, 194
Lower airway dysfunction, anesthesia for patients with, 396–398
induction, 397
maintenance, 397
mechanical ventilation, 397
Lower airway dysfunction, anesthesia for patients with (cont’d)
premedicants, 396–397
recovery, 397–398
Lower lip, nerve block in dogs, 354
Lumbosacral epidural analgesia in cats, 374–376, 375f
in dogs, 360–368, 361f, 364t, 365t adverse effects, 367–368
continuous epidural anesthesia, 362–363
epidural nonopioid analgesia, 366–367
epidural opioid analgesia, 365–366
local anesthetic choice, 363, 365
local anesthetic doses, 364t
needle placement, 360–361, 361f
opioid properties, 365t
procedure, 360–362, 361f
in orthopedic patients, 501
Lung volumes, 26–27, 27f
Lusitropy, 25
Lymphatic system, 18
MAC (minimum alveolar concentration), 67–68
MacIntosh blade, 164, 165, 165f
Magill endotracheal tube, 163
Magnetic resonance imaging (MRI), 506–508, 508t
anesthetic concerns during, 405
contrast agents, 506
safety considerations, 506–508, 508t
Maintenance of anesthesia goals, 287b
in neonatal and geriatric patients, 495
overview, 284–286
in renal disease patients, 418t
in respiratory disease patients
lower airway disease, 397
pharmacology, 392
upper airway disease, 395
supplemental systemic analgesics, 296t
in traumatized and critically ill patients, 488
Malignant hyperthermia, 73, 525–526
Mandible and lower teeth nerve block in cats, 369–370, 370f
nerve block in dogs, 354
Mandibular muscle tone (jaw tone), as anesthetic depth indicator, 199
Mandibular nerve, desensitization of, 498, 501
in cats, 369, 370f
in dogs, 352, 352f
Mannitol after cardiopulmonary resuscitation (CPR), 520
ophthalmic indications and side effects, 465t
for reducing intracranial pressure (ICP), 406
in renal disease patients, 418t, 419
Manometer, for measuring endotracheal tube cuff pressure, 227
Mapleson systems, 180–181, 182f
Marmots, 320
Marsupials, 324
Massage therapeutic, 143–144
in water, 144
Maxilla and upper teeth, nerve block for, 369–370, 370f, 498
Maxillary nerve, desensitization of, 352–353, 352f, 439
McGill Pain Questionnaire, 95
Mean arterial blood pressure (MAP) calculation of, 208
cerebral blood flow and, 401f
fluid balance assessment and, 266
formula for estimation of, 20
monitoring, 208–209
in neonatal patients, 496
optimal and adequate hemodynamic end points for volume resuscitation, 481t
in renal disease patients, 418
Mechanical ventilation in lower airway dysfunction patients, 397
in traumatized and critically ill patients, 489
Medetomidine analgesia, 129
cardiovascular effects, 380t, 381
in cesarean section patients, 473t
described, 45–47
dosage ranges, 129t
in liver disease patients, 425
in neurological disease patients, 403
ocular effects, 466t
respiratory effects, 391
in rodents and rabbits, 316t
Medial plantar nerve block, 373f
Median effective dose (ED50), 67, 68
Median nerve block in cats, 371, 372f
Medical gas supply, 165–168
cylinders, 166, 166t
pressure gauge, 168
regulator, 167–168
safety, 166–167
color coding, 167
DISS (diameter index safety system), 167
PISS (pin index safety system), 167
quick connectors, 167
Megaesophagus, 436–437, 436t
Meloxicam
as antipyretic agent, 120
chronic use in cats, 153
dosage ranges, 126t
for injectable postoperative analgesics, 288t
ocular effects, 467t
for oral postoperative analgesics, 289t
for osteoarthritis, 123
overview of, 124, 126
in rodents and rabbits, 313t
Meninges, 37
Mental nerve, desensitization of
in cats, 369, 370, 370f
in dogs, 352, 352f
Meperidine
adverse effects, 109
clinical uses, 109
dosage ranges, 106t
for epidural use, 365t
metabolism of, 109
overview of, 108–109
serotonin syndrome and, 109
Mepivacaine. See also Local anesthetics
in cesarean section patients, 474t
doses for peripheral and epidural block procedures, 364t
infiltration anesthesia, 351
metabolism of, 343
properties, 332t
trade name, structure, and main uses, 330t
Meridians, acupuncture, 133–134
Metabolic (fixed) acid, 242
Metabolic acidosis. See also Acid-base balance
after cardiopulmonary resuscitation (CPR), 517
causes, 248t
compensatory changes, 249f, 250t
in diabetes mellitus, 457
perianesthetic fluid therapy for, 264
Metabolic alkalosis. See also Acid-base balance
causes, 248t
compensatory changes, 249f, 250t
perianesthetic fluid therapy for, 264
Metabolism, of inhalation anesthetic agents, 65–66
Methadone
dosage ranges, 106t
for epidural use, 365t
overview of, 111
Methazolamide, ophthalmic indications and side effects of, 465t
Methemoglobinemia
local anesthetics and, 346
treatment, 348
Methohexital sodium, 52
Methoxyflurane
nephrotoxicity, 71
physical and chemical characteristics, 58t, 59t
Methylene blue, 348
Mice. See also Laboratory mammal anesthesia
anesthetic drugs for use in, 303t, 306
fluid volumes for administration, 311t
physiological data for, 301f
routes of injection, 318t
Midazolam
for anesthesia co-induction, 286t
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
cardiovascular effects, 380, 380t
in cesarean section patients, 473t
described, 49–50
for exploratory laparotomy, 443
in GI endoscopy patients, 440
for induction in patients with trauma and/or hemodynamic instability, 292t
in intramuscular anesthetic protocol in cats, 285t
in liver disease patients, 428
ocular effects, 467t
in orthopedic patients, 500
preanesthetic use, 282t
in renal disease patient anesthesia, 418t
in respiratory disease patients, 393–394
in rodents and rabbits, 316t
Midazolam/ketamine, for anesthesia induction, 286t
Miller blade, 164, 165, 165f
Mink, 322
Minute ventilation (MV)
defined, 218
normal values, 218
Miosis, from opioids, 103
Mivacurium
in cesarean section patients, 474t
in liver disease patients, 427
pharmacology, 80
Mixed acid-base disorders, 250
Modified Jackson-Rees system, 181, 182f, 183
Monro-Kellie hypothesis, 39
Morphine
adverse effects, 107
for analgesia in maintenance phase of anesthesia, 296t
cardiocirculatory effects, 380
in cesarean section patients, 473t
clinical use, 107–108
for corneal ulcers, 468
dosage ranges, 106t
epidural use, 376
for epidural use, 365–366, 365t, 398
for extending effect of local anesthetics, 498
for injectable postoperative analgesics, 288t
metabolism of, 107
ocular effects, 467t
for oral postoperative analgesics, 289t
overview of, 107–108
pharmacology, 107
preanesthetic use, 282t
in renal disease patient anesthesia, 418t
respiration depression from, 521
in respiratory disease patients, 392
in rodents and rabbits, 313t, 314
subarachnoid injection, 527
Movement, as anesthetic depth indicator, 198
MRI. See Magnetic resonance imaging (MRI)
Mucous membrane color, assessment of, 204
Mu (μ) receptor
agonist-antagonists, 112–114
agonists, 105–112
antagonists, 115–116
antinociception, 136–137
described, 9, 99–102
partial agonist, 114–115
Murphy endotracheal tube, 160, 161f
Muscle fasciculations, from succinylcholine, 77
Muscle hypertonus, as anesthetic depth indicator, 198
Muscle relaxants
individual drugs
atracurium, 78–79
cisatracurium, 79
doses, 77t
doxacurium, 80
mivacurium, 80
pancuronium, 78
rocuronium, 79
succinylcholine, 78
vecuronium, 79
neuromuscular blockade, 75–81
pharmacology, 75–81
precautions, 80
reversal of, 80–81
Musculoskeletal inflammation/injury, chronic pain and, 148t
Myasthenia gravis, 437
Mydriasis, from opioids, 103
Myelography, anesthetic management during, 406
Myoclonus (muscle twitching), as anesthetic depth indicator, 198
Myotoxicity of local anesthetics, 345–346
Nalbuphine, 114
Nalmefene, 116
Naloxone
for opioid reversal, 287, 391
overview of, 116–117
use in newborns, 476
Naltrexone, 116
National Animal Poison Control Center (NAPCC), 345
National Center for Complementary and Alternative Medicine (NCCAM), 132
Natural killer (NK) cell, suppression of activity of, 149
Nausea
acupuncture for, 139–140
opioids and, 103
Necrotizing fasciitis, NSAID administration and, 122
Needles, acupuncture, 137

Neonatal patients
anesthetic drug selection for, 290
anesthetic induction, 494–495
anesthetic maintenance, 495
care of newborns, 476
general considerations, 490
patient evaluation and preparation, 491–493
physiology, 490, 491t
preanesthetic period, 493–494
supportive care, 495–496

Neostigmine, 81

Nephrotoxicity, of inhalant anesthetic agents, 71–72

Nerve blocks
in cats, 369–377
brachial plexus block, 371–373
epidural opioid analgesia, 376
face, 369, 370f
intercostal nerve block, 373–374, 374f
IVRA, 372–373
limb, 371
lumbosacral epidural anesthesia,
374–376, 375f
mandible and lower teeth, 369–370,
370f
maxilla and upper teeth, 369–370, 370f
peroneal and tibial nerves, 371, 373f
radial, ulnar, and median nerves, 371,
372f
complications, 527
in dental patients, 497–498
differential nerve blockade, 329–335
brachial plexus infiltration, 332, 334,
334f
classification of nerve fibers and order of
blockade, 333t
epidural and spinal blockade, 335
in situ studies, 332
in dogs, 348–368
brachial plexus block, 357–359, 358f
eye and orbit, 353–354
face, 352–353, 352f
foot and leg anesthesia, 357–360
intercostal nerve block, 354–355, 355f
interpleural regional analgesia, 355–357
intra-articular analgesia, 357
IVRA, 359–360
lower lip, 354
lumbosacral epidural analgesia, 360–368,
361f, 364t, 365t
mandible and lower teeth, 354
peripheral nerve stimulator use, 357–359,
359f
ring block, 357

Nerve conduction studies, anesthetic
management studies, 408

Nerve stimulator, for monitoring
neuromuscular function, 226

Nervous system. See also Central nervous
system (CNS)
anatomy and physiology, 35–41
autonomic nervous system, 40
brain
anatomy, 35
physiology, 35–37
cardiovascular system regulation by, 20–21
cerebrospinal fluid (CSF), 37–39, 38f
disease (See Neurological disease patients,
anesthesia for)
neuron function, 40–41
axonal conduction, 40
neuroregulators, 40–41
spinal nerves, 37
Nervous tissue inflammation/injury, chronic
pain and, 148t

Neuralgia, 84
Neuritis, 84

Neurogenic shock, 483
Neuroleptanalgesics, in neurological disease
patients, 403

Neurological disease patients, anesthesia for
anesthetic management
for electrodiagnostic techniques, 407
during electroencephalography, 407–408
for elevated intracranial pressure (ICP),
406
for intervertebral disc disease, 405–406
for intracranial masses, 406
during MRI, 405
during myelography, 406
during nerve conduction studies, 408
of seizures, 407
using bispectral index (BIS), 408
pharmacology, 402–405
cardiovascular supportive drugs,
404–405, 404t
inhaltant anesthetics, 404
Neurological disease patients, anesthesia for (cont’d)
injectable anesthetics, 403
neuromuscular blocking agents (NMBAs), 404
sedatives, tranquilizers, and analgesics, 402–403
physiology, 400–402
Neuromuscular junction, physiology of, 76
Neuromuscular blockade monitoring, 226
for ophthalmic surgery, 468
Neuromuscular blocking agents (NMBAs), 75–81. See also specific agents
depolarizing and nondepolarizing, 76–77, 468
in GI endoscopy patients, 440
individual drugs
atracurium, 78–79
cisatracurium, 79
doses, 77t
doxacurium, 80
mivacurium, 80
pancuronium, 78
rocuronium, 79
succinylcholine, 78
vecuronium, 79
in neurological disease patients, 404
neuromuscular junction, physiology of, 76
in obese patients, 451
for ophthalmic surgery, 468
in portosystemic shunt patients, 430
precautions, 80
reversal of, 80–81
Neuromuscular electrical stimulation (NMES), 145
Neuron function
axonal conduction, 40
neuroregulators, 40–41
Neuropathic pain, 84, 91–92
Neuropathy, 84
Neuroregulators, 40–41
Neurosteroids, 52–53
Neurotoxicity, of local anesthetics, 345
NICO monitor, 213
Nitrous oxide (N₂O)
action and toxicity, 73–75
in cesarean section patients, 474t
MAC (minimum alveolar concentration), 68
ocular effects, 466t
physical and chemical characteristics, 58t, 59t, 61–62
transfer to closed gas spaces, 74–75
in traumatized and critically ill patients, 488
NK (natural killer) cell, suppression of activity of, 149
NMBAs. See Neuromuscular blocking agents (NMBAs)
NMES antagonists, for chronic pain, 155
NMES (neuromuscular electrical stimulation), 145
N-methyl-D-aspartate (NMDA)
amantadine and, 130
gabapentin and, 130
ketamine and, 129
receptors, 55, 89, 92
N₂O. See Nitrous oxide (N₂O)
Nociceptin opioid peptide (NOP) receptor, 99, 100–101
Nociception, 84
Nociceptive pain, 84
Nociceptive pathways, 85–88
ascending spinal pathways, 87–88
divergence in pathways, 86
nociceptors, 85–86
trigeminal system, 88
Nociceptors
described, 84
pain modulation, 88–89
silent, 86, 88
stimulation of, 85–86
Nociceptor threshold, 84
Nonrebreathing systems
described, 180–183
diagrams of, 182f
mounting blocks, 183
patient size, 180
pressure manometer, 183, 184f
Nonsteroidal anti-inflammatory drugs (NSAIDs), 116–128. See also specific drugs
biotransformation, 153
cardiovascular effects, 382
in cats, 153
for chronic pain, 152–153
contraindications, 124
COX-2-selective, 119, 120, 124, 126
cyclooxygenase and, 152
Index  557

in dental patients, 498
endogenous mechanisms, 120–121
fever inhibition, 120
for injectable postoperative analgesics, 288t
in liver disease patients, 425–426
monitoring therapy, 153
ocular effects, 467t
for oral postoperative analgesics, 289t
for orthopedic pain, 503
patient selection/therapeutic considerations, 121–122
pharmacology, 121
preanesthetic use, 280
in respiratory disease patients, 392
side effects, 152
in small mammals, 312, 314
specific drugs, 124–128
acetaminophen, 127–128
aspirin, 128
carprofen, 126
deracoxib, 126–127
dipyrone, 128
dosage ranges, 125t
etodolac, 126
firocoxib, 126–127
ketoprofen, 126
ketoxyloxamic acid, 127
meloxicam, 124, 126
piroxicam, 127
tepoxalin, 127
tolfenamic acid, 127
vedaprofen, 127
uses, 121–124
inflammatory conditions, 122
osteoarthritis, 123
perioperative, 121–122
postoperative, 122
NOP (nociceptin opioid peptide) receptor, 99, 100–101
Nordiazepam, 49
Norepinephrine, for cardiovascular support, 485t
Normeperidine, 109
Noxious stimulus, 84
NSAIDs. See Nonsteroidal anti-inflammatory drugs (NSAIDs)
Numby Stuff patches, 341

Nutraceutical products, for chronic pain, 157
Nutria, 320

Obesity, 436t, 448–452, 449f, 450f
Occupational exposure, to inhalation anesthetic agents, 75
OCR (oculocardiac reflex), 462, 463, 464
Ocular patients, 461–469
analgesia agents, 464–465, 467t
anesthetic and sedative agents, 464, 466t–467t
chronic pain and, 148t
electroretinography (ERG), 468–469
general considerations, 461–463
local and regional anesthesia, 465, 468
neuromuscular blockade, 468
ophthalmic medications, 464, 465t
patient monitoring, 462
patient positioning, 461–462
physiological considerations, 463–464
recovery, 463
Oculocardiac reflex (OCR), 462, 463, 464
OER (oxygen extraction ratio), 203–204
Ohm’s law, 19
Oliguria, from opioid use, 104
Omeprazole, 442
Onychectomy, nerve blocks for, 371
Ophthalmic medications, 464, 465t
Ophthalmic nerve, desensitization of, 352, 352f
Opioid receptors, 99–102
endogenous receptor ligands, 100–101
peripheral, 102
types, 99–100
Opioids, 99–116. See also specific drugs
administration routes, 102
adverse effects, 102–105
 cardiovascular system, 104
 CNS, 103
gastrointestinal system, 104
 genitourinary system, 104–105
 respiratory system, 103–104
agonist-antagonists, 112–115
buprenorphine, 114–115
butorphanol, 113–114
lock-and-key analogy of action, 112f
nalbuphine, 114
overview, 112–113
pentazocine, 114
Opioids (cont’d)
agonists, 105–112
  alfentamil, 111
codeine, 111
dosage ranges, 106t
fentanyl, 109–110
hydrocodone, 111–112
hydromorphone, 108
lock-and-key analogy of action, 105f
meperidine, 108–109
methadone, 111
morphine, 107–108
oxycodone, 111–112
oxymorphone, 108
remifentanil, 111
sufentanil, 111
for analgesia in maintenance phase of anesthesia, 296t
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
antagonists, 115–116
cardiovascular effects, 379–380, 380t, 512
for chronic pain, 154–155
in dental patients, 498
distribution and therapeutic implications, 101–102
effect on control of ventilation, 32
endogenous receptor ligands, 100–101
for epidural use, 365–366, 365t, 367, 398, 490
for exploratory laparotomy, 443
for extending effect of local anesthetics, 498
hypoventilation from, 403
for induction in patients with trauma and/or hemodynamic instability, 292t
for injectable postoperative analgesics, 288t
interactions among, 9
in intramuscular anesthetic protocol in cats, 285t
in intramuscular anesthetic protocol in dogs, 284t
in liver disease patients, 424, 425, 428
in neonatal and geriatric patients, 493
in neurological disease patients, 403
in obese patients, 452
ocular effects, 467t
for oral postoperative analgesia, 289t
in orthopedic patients, 500
overview, 99–100
partial agonists, 112–113, 113f
preanesthetic use, 279, 282t
pupil size, effect on, 463
in renal disease patient anesthesia, 418t
renal effects, 414
respiration depression from, 391, 520–521
in respiratory disease patients, 391, 393, 395–396
in rodents and rabbits, 313t, 314
in shock, 486
signaling and mechanisms of, 101
for thoracic surgery patients, 398
in traumatized and critically ill patients, 488
use in cats, 154–155
Oral disease, 434–436, 436t
Orbit, nerve block in dogs, 353–354
Orphanin FQ receptor, 99, 100–101
Orthopedic patients, 499–504
anesthetic induction, 500–501
chronic pain, management of, 503–504
general considerations, 499
local and regional anesthesia/analgesia, 501
patient evaluation and preparation, 499
patient monitoring, 501–502
preanesthetic period, 499–500
recovery, 502–503
supportive care, 502
systemic analgesics, 501
Oscillometric method for ABP determination, 209–210
Osmolality, 258
Osmolarity, 258
Osmole (Osm), 258
Osmosis, 258
Osmotic pressure, 258. See also Colloidal osmotic pressure (COP)
Osteoarthritis, NSAIDs for, 123
Ostwald solubility coefficient, 64
Otoscope, for endotracheal tubes placement in small mammals, 307–309
Overdrive suppression, 22
Overinflation of lungs, 526
Oxycodone
dosage ranges, 106t
for oral postoperative analgesics, 289t
overview of, 111–112
Oxygen, requirements for brain function, 35–36
Oxygen administration
hypoxemia response to, 389t
maternal, 475
for newborns, 476–477
for pulmonary edema, 395

Oxygenation
assessment in small mammals, 307
key factors relating to, 202f
monitoring, 213–218
objective methods, 215–218
oxygen bound to hemoglobin, 216–218
oxygen dissolved in arterial blood (PaO₂), 215–216
subjective methods, 214–215
patient evaluation, 6

Oxygen consumption (VO₂), 202–203

Oxygen debt, 379

Oxygen delivery (DO₂)
factors relating to, 202f
monitoring, 201–204

Oxygen extraction ratio (OER), 203–204

Oxygen flush valves, 173–174

Oxygen transport
in blood, 18–19
respiratory system and, 28–30

Oxyglobin, 511

Oxyhemoglobin dissociation curve, 214f

Oxymorphone
for analgesia in maintenance phase of anesthesia, 296t
in cesarean section patients, 473t
dosage ranges, 106t
for epidural use, 365t
for induction in patients with trauma and/or hemodynamic instability, 292t
for injectable postoperative analgesics, 288t
ocular effects, 467t
overview of, 108
preanesthetic use, 282t
respiration depression from, 521
in rodents and rabbits, 313t
in shock, 486

Oxytocin, 470

PABA (paraaminobenzoic acid), 343

Packed cell volume (PCV), serial assessments of, 267

PaCO₂. See Arterial carbon dioxide partial pressure (PaCO₂)

Pain, 82–146
AAHA management standards, 4, 5t
acute
assessment of, 93–96, 95f, 97f
defined, 83
breathing-associated, 398
chronic
assessment of, 96, 98, 150–151, 150t
behaviors associated with, 150t
conditions associated with, 148t
defined, 83, 84
management of, 147–157
in orthopedic patients, 503–504
definitions of, 82–85
evaluation, preanesthetic, 4
importance of alleviating, 149–150
management (See Pain Management)
measuring in patients, 92–98
acute pain, 93–96
frequency of assessment, 96
objective measures, 93–94
subjective scoring systems, 94–96, 95f, 97f
chronic pain, 96, 98
dynamic and interactive visual analog scale (DIVAS), 94–95
Glasgow Composite Measures Pain Scale, 95–96, 97f
McGill Pain Questionnaire, 95
University of Melbourne Pain Scale (UMPS), 95
visual analog scale (VAS), 4, 94, 95f
modulation, 88–91
in dorsal horn, 89–91, 90f
in periphery (nociceptors), 88–89
supra segmental, 91
neuroanatomy of nociceptive pathways, 85–88
ascending spinal pathways, 87–88
divergence in pathways, 86
nociceptors, 85–86
trigeminal system, 88
neuropathic
defined, 84, 91
described, 91–92
in small mammals
alleviation, 312, 313t, 314
assessment, 311–312
visceral, 87
Pain management, 98–146
acupuncture, 131–140
analgesic adjuvants, 128–131
alpha2-adrenergic agents, 129
amantadine, 130
dosage ranges, 129t
gabapentin, 129–130
ketamine, 129
overview, 128–129
tapendadol, 131
tramadol, 130–131
in cesarean section patients, 477
chronic pain, 147–157
assessment of chronic pain, 150–151, 151t
barriers to effective control, 147
basic approach to, 148–149
conditions associated with chronic pain, 148t
general considerations, 147–149
importance of alleviation, 149–150
principles of alleviation, 151–152
steps to overcoming barriers to control, 147
therapeutic agents, 152–157
acetaminophen, 154
acupuncture, 157
anticonvulsants, 156
bisphosphonates, 157
combination analgesics, 156
NMDA antagonists, 155
NSAIDs, 152–153
nutraceuticals, 157
opioids, 154–155
radiation, 157
steroids, 156–157
tricyclic antidepressants, 156
importance of, 149–150
nonsteroidal anti-inflammatories (NSAIDs), 116–128
contraindications, 124
endogenous mechanisms, 120–121
fever inhibition, 120
mechanisms of analgesia, 118–120
patient selection/therapeutic considerations, 121–122
pharmacology, 121
specific drugs, 124–128
acetaminophen, 127–128
aspirin, 128
carprofen, 126
deracoxib, 126–127
dipyrone, 126
dosage ranges, 125t
etodola, 126
firocoxib, 126–127
ketoprofen, 126
ketorolac, 127
meloxicam, 124, 126
piroxicam, 127
tepoxalin, 127
tolfenamic acid, 127
vedaprofen, 127
uses, 121–124
inflammatory conditions, 122
osteoarthritis, 123
perioperative, 121–122
postoperative, 122
opioids, 99–116
adverse effects, 102–105
cardiovascular system, 104
CNS, 103
gastrointestinal system, 104
genitourinary system, 104–105
respiratory system, 103–104
agonist-antagonists, 112–115
buprenorphine, 114–115
butorphanol, 113–114
lock-and-key analogy of action, 112f
nalbuphine, 114
overview, 112–113
pentazocine, 114
agonists, 105–112
alfentamil, 111
codeine, 111
dosage ranges, 106t
fentanyl, 109–110
hydrocodone, 111–112
hydromorphone, 108
lock-and-key analogy of action, 105f
methadone, 111
morphine, 107–108
oxycodone, 111–112
oxymorphone, 108
remifentanil, 111
sufentanil, 111
antagonists, 115–116
distribution and therapeutic implications, 101–102
endogenous receptor ligands, 100–101
overview, 99–100
partial agonists, 112–113, 113f
signaling and mechanisms of, 101
in orthopedic patients, 503–504
overview, 98–99
rehabilitation therapy, 140–146
aquatic-based, 144
electrical stimulation, 145–146
local hyperthermia, 142
local hypothermia, 141–142
overview, 140–141
passive range of motion (PROM), 142–143
therapeutic exercise, 144
therapeutic massage, 143–144
therapeutic ultrasound, 145
in small mammals, 312, 313t, 314
for thoracic surgery patients, 398
traditional Chinese medicine (TCM), 131–140
Pain (detection) threshold, 84
Pain tolerance, 84
Pain-tolerance range, 84
Palpebral eye reflexes, 463
Palpebral reflex, as anesthetic depth indicator, 199
Palpometer, 93
Pancreas, disorders of, 457–458
diabetes insipidus, 457–458
diabetes mellitus, 457
insulinoma, 458
Pancreatic lipase immunoreactivity (PLI), 447
Pancreatitis, 436t, 447–448
Pancuronium, 436t, 447–448
doses, 77t
pharmacology, 78
Panosteitis, NSAIDs for, 123–124
\( \text{PaO}_2 \). See Arterial oxygen partial pressure (\( \text{PaO}_2 \))
\( \text{PAO}_2 \) (partial pressure of alveolar oxygen), 215–216
Paraaminobenzoic acid (PABA), 343
Parasympatholytic drugs. See Anticholinergics
Parathyroid gland, 458–459
Paresthesia, 84
Partial pressure of alveolar oxygen (\( \text{PAO}_2 \)), 215–216
Partial pressure of arterial carbon dioxide. See
Arterial carbon dioxide partial pressure (\( \text{PaCO}_2 \))
Partial pressure of arterial oxygen. See
Arterial oxygen partial pressure (\( \text{PaO}_2 \))
Partition coefficient (PC)
  blood-gas, 64
  solvent-gas, 59t, 64
Passive range of motion (PROM) exercise, 142–143
Patient monitoring, 197–239
circulation, 204–213
  objective methods, 205–213
  arterial blood pressure, 208–211, 211f
  cardiac output, 212–213
  cardiac rhythm, 207–208, 207f
  central venous pressure, 211–212
  heart rate or pulse rate, 205–206
  subjective methods, 204–205
  capillary refill time (CRT), 204
  pulse palpation, 204–205
CNS function, 198–200
  objective methods, 199–200
  subjective methods, 198–199
complications, management of common
  anesthetic, 227–239
  bradycardia and bradyarrhythmias, 228–229, 228t, 229f
  hypertension, 233–234
  hyperthermia, 239
  hyperventilation and hypocapnia, 238
  hypotension, 231–233, 233t
  hypothermia, 238–239
  hypoventilation and hypercapnia, 237–238
  hypoxemia, 234–237, 235t
  tachycardia and tachyarrhythmias, 228t, 230–231, 230f, 231f
endotracheal tube cuff inflation pressure, 227
gastroesophageal reflux (GER), 226–227
laboratory valves, 226
in neonatal and geriatric patients, 495
neuromuscular blockade, 226
Patient monitoring (cont’d)
in ocular patients, 462
in orthopedic patients, 501–502
oxygenation, 213–218
objective methods, 215–218
  oxygen bound to hemoglobin, 216–218
  oxygen dissolved in arterial blood
  \( \text{PaO}_2 \), 215–216
subjective methods, 214–215
oxygen delivery (DO2), 201–204, 202f
physiological consequences of anesthesia, 201
in renal disease patients, 418
renal function, 226
thermo regulation, 225
in traumatized and critically ill patients, 488
ventilation, 218–225
objective methods, 219–225
  arterial partial pressure of \( \text{CO}_2 \), 220–221
  end-tidal CO2 (ETCO2), 221–225, 221f, 223f, 224f, 224t
  respiratory rate, 219–220
  tidal volume, 220
subjective methods, 219
Patient preparation, 5–7
  heart disease, 6
  hepatorenal disease, 6
  oxygenation and ventilation, 6
  patient positioning, 6–7
  preanesthetic fasting, 5
  preanesthetic fluid therapy, 5–6
  prophylactic antibiotic administration, 6
PC. See Partition coefficient (PC)
PCV (packed cell volume), serial assessments of, 267
PEA (pulseless electrical activity), 513, 517, 518
Pediatric patients, anesthetic drug selection for, 290
PEEP. See Positive end-expiratory pressure (PEEP)
Pentazocine, 114
Pentobarbital sodium, 51
Perception, pain, 98
Periaqueductal gray matter, 86, 91
Peribulbar anesthesia, 353
Peripheral nerve stimulator, 357–359, 359f
Peritonitis, 447, 448
Perivascular injection, 520
Peroneal nerve block in cats, 371, 373f
Pethidine, in rodents and rabbits, 313t
Pétrissage, 143
PH. See also Acid-base balance
defined, 241
  local anesthetic alkalinization, 337–338
Pharmacology
  anticholinergic drugs, 41–43
  inhalation anesthetic agents, 57–75
  injectable anesthetic agents, 50–57
  muscle relaxants and neuromuscular blockade, 75–81
  sedatives, 44–50
Pharyngeal disease, 434–436, 435f, 436t
Phenobarbital sodium, 51
Phenolphthalein, 179
Phenothiazines
dysrhythmias from, 512
  in liver disease patients, 424
  pharmacology, 44
  renal effects, 414
  respiratory effects, 388–389
Phenylephrine
  for cardiovascular support, 485t
  ophthalmic indications and side effects, 465t
Pheochromocytoma, 456
Phosphate buffer system, 244
PH-stat hypothesis, 247
Physical status, classification of, 4t
Physiological consequences of anesthesia, 201
Pia mater, 37
Pickwickian syndrome, 451
Pilocarpine, ophthalmic indications and side effects of, 465t
Pin index safety system (PISS), 167
Piperoxuronium, 77t
Piroxicam
dosage ranges, 126t
  overview of, 127
PKa, 241
Placental transfer of drugs, 471–472
Plasma, 271
PLI (pancreatic lipase immunoreactivity), 447
Pluronic lecithin organogel (PLO gel) delivery of fentanyl, 110
Pneumothorax
tension, 500
  thoracostomy tube placement, 500
Poiseuille-Hagen law, 19
Polyuria, 26
Polyuria, in diabetes insipidus, 457–458
Pontocaine cream, 350
Pores of Kohn, 34
Portosystemic shunts, 422, 429–430
  interventional radiology, 429–430
  laparotomy, 430
Positioning of patients, 6–7
Positive end-expiratory pressure (PEEP)
  for hypoxia after functional residual capacity (FRC) changes, 522
  in lower airway disease patients, 397
Positive pressure ventilation (PPV), for hypoxemia during anesthesia, 236
Potassium, for hyperparathyroidism, 458
Potentiation, drug, 8
PPV (positive pressure ventilation), for hypoxemia during anesthesia, 236
PQ interval, 22
Prairie dogs, 319
PRBCs, 273
Preanesthesia
  agents for use in rodents and rabbits, 316t
  in upper airway dysfunction patients, 393–394
Preanesthetic evaluation, 3–5
  pain evaluation, 4, 5t
  physical status classification, 4, 4t
  stress evaluation, 4–5
Preanesthetic medication, 279–280
  common medications in cats, 282t
  common medications in dogs, 282t
  dysrhythmias from, 512
  goals of, 280b
  steps in selecting, 281f
Preanesthetic patient evaluation form, 275f
Preanesthetic period
  in neonatal and geriatric patients, 493–494
  in orthopedic patients, 499–500
  in renal disease patients, 417
  in traumatized and critically ill patients, 486–487
Prednisolone acetate, ophthalmic indications and side effects of, 465t
Preexisting disease conditions, anesthetic drug selection and, 292–293
Pregnancy
  cesarean section patients, 469–477
  local anesthetic use in, 339
  NSAID contraindication during, 124
  physiological alterations induced by, 469, 470t
  placental transfer of drugs, 471–472
  uterine blood flow during, 469–470
Preload, 24, 379
Premature atrial complex, 231f
Premature ventricular complex, 230, 230f, 512
Pressure
  barometric, 61
  partial pressure, 60
  resistance, flow, and, 19
  vapor, 61
Pressure gauges, 168
Pressure manometer, 183, 184f
Pressure reducing valve, 167–168
Prilocaine. See also Local anesthetics
  metabolism of, 343
  properties, 332t
  trade name, structure, and main uses, 330t
PR interval, 22
Procainamide
  for arrhythmias/dysrhythmias, 486t, 512
  intravenous dose for heart rate/rhythm abnormalities, 228t
  for tachyarrhythmias, 230
Procaine. See also Local anesthetics
  doses for peripheral and epidural block procedures, 364t
  metabolism of, 343
  properties, 332t
  trade name, structure, and main uses, 331t
Procyonids, 323–324
PROM (passive range of motion) exercise, 142–143
Proparacaine
  corneal desensitization, 369
  topical use, 349
Propofol
  for anesthesia induction, 286t
  apnea and, 521
  cardiovascular effects, 380t, 382
  in cesarean section patients, 473t
  for exploratory laparotomy, 443
  in GI endoscopy patients, 440
Propofol (cont’d)
for induction in patients with trauma and/or hemodynamic instability, 292t
for intubation, 394
in liver disease patients, 426
in neonatal and geriatric patients, 494
in neurological disease patients, 403
in obese patients, 451
ocular effects, 466t
in orthopedic patients, 500
pharmacology, 54
in renal disease patient anesthesia, 418t
renal effects, 414t, 415
in respiratory disease patients, 394, 395, 397
respiratory effects, 391
Prostaglandins
cyclooxygenase and production of, 116–118, 117f
NSAIDs and inhibition of, 118
Protein buffer system, 244
Pseudocholinesterase, 78, 80
Pulmonary barotrauma, 526
Pulmonary circulation, 17f
Pulmonary edema, 395
Pulmonary shunt flow, 33
PulseCO monitor, 213
Pulseless electrical activity (PEA), 513, 517
Pulse oximeter, 206, 218
Pulse oximetry
in GI endoscopy patients, 439
for hemoglobin saturation measurement, 217–218
for ocular patients, 462
for patient monitoring, 206, 217–218, 219
in renal disease patients, 418
Pulse palpation
locations for, 205–206
for patient monitoring, 204–206
in small mammals, 309
Pulse pressure, monitoring, 204–205
Pulse-pressure waveform analysis, 20
Pulse rate
assessment in small mammals, 307
monitoring, 205–206
Pupillary light reflex, as anesthetic depth indicator, 199
Pupil size, 93, 463
Purkinje fibers, 24
P wave, 22
Pyridostigmine, 81
QT interval, 24
Rabbits. See also Laboratory mammal anesthesia
anesthesia, general considerations in, 315–316
anesthetic drugs for use in, 302, 303t–304t, 305
endotracheal tubes placement in, 307–308, 308f
fluid volumes for administration, 311t
physiological data for, 301f
routes of injection, 318t
Raccoon, 323
Radial nerve block in cats, 371, 372f
Radiation therapy, 157, 508
Radiculalgia, 85
Radiculitis, 85
Radiculopathy, 85
Rats. See also Laboratory mammal anesthesia
anesthetic drugs for use in, 303t, 305–306
fluid volumes for administration, 311t
IP (intraperitoneal) injection, 315, 317f
physiological data for, 301f
routes of injection, 318t
RBF. See Renal blood flow (RBF)
Reactions, defined, 85
Rebreathing bag, 177
Rebreathing system, 175–180
APL (adjustable pressure-limiting) valve, 177–178, 178f
breathing circuit/tubing, 176–177
carbon dioxide absorbents, 179–180
carbon dioxide absorber, 178–179
expiratory one-way valve, 177
fresh gas inlet, 176
full (complete), 175
inspiratory one-way valve, 176
partial, 175
reservoir bag, 177
Record keeping, 13f, 14
Recovery from anesthesia, 286–288
injectable postoperative analgesics, 288t
in ocular patients, 463
oral postoperative analgesics, 289t
in orthopedic patients, 502–503
in respiratory disease patients
  lower airway dysfunction, 397–398
  upper airway dysfunction, 395–396
in small mammals, 310–311
in traumatized and critically ill patients, 490

Reflexes
as anesthetic depth indicator, 198
defined, 85

Regional anesthesia
for cesarean section, 475–476
in dental patients, 497–498
in obese patients, 451
in ocular patients, 465, 468
in orthopedic patients, 501
in traumatized and critically ill patients, 489–490

Regional nerve blocks
in cats, 369–377
  brachial plexus block, 371–373
  epidural opioid analgesia, 376
  face, 369, 370f
  intercostal nerve block, 373–374, 374f
  IVRA, 372–373
  limb, 371
  lumbosacral epidural anesthesia, 374–376, 375f
  mandible and lower teeth, 369–370, 370f
  maxilla and upper teeth, 369–370, 370f
  peroneal and tibial nerves, 371, 373f
  radial, ulnar, and median nerves, 371, 372f
complications, 527
in dental patients, 497–498
in dogs, 348–368
  brachial plexus block, 357–359, 358f
  eye and orbit, 353–354
  face, 352–353, 352f
  foot and leg anesthesia, 357–360
  intercostal nerve block, 354–355, 355f
  interpleural regional analgesia, 355–357
  intra-articular analgesia, 357
  IVRA, 359–360
  lower lip, 354
  lumbosacral epidural analgesia, 360–368, 361f, 364t, 365t
  mandible and lower teeth, 354
  peripheral nerve stimulator use, 357–359, 359f
  ring block, 357

Regulator, 167–168

Rehabilitation therapy, 140–146
  aquatic-based, 144
  electrical stimulation, 145–146
  local hyperthermia, 142
  local hypothermia, 141–142
overview, 140–141
passive range of motion (PROM), 142–143
therapeutic exercise, 144
therapeutic massage, 143–144
therapeutic ultrasound, 145

Remifentanil
for analgesia in maintenance phase of anesthesia, 296t
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
dosage ranges, 106t
for induction in patients with trauma and/or hemodynamic instability, 292t
overview of, 111

Renal blood flow (RBF)
anesthetics effect on, 414–415, 414t
increase with
  dopamine, 419
  fenoldopam, 419
  mannitol, 419
regulation of, 412–413

Renal function
monitoring, 226

Renal system, 412–420
adjunctive treatments in patients with disease, 419
anesthetic effects on, 414–415, 414t
disease
anesthetic management in patients with, 417–418, 418t
effects on anesthesia, 416–417
fluid therapy considerations with, 265
inhalation anesthetic agent action and toxicity, 71–72
management of patients with post-renal disease, 419–420
nephrotoxicity of inhalant anesthetic agents, 71–72
NSAIDs adverse effects on, 119, 121–122, 152
Renal system (cont’d)
  pathophysiology, 413–414
  acute renal failure, 413
  chronic renal failure, 413–414
  physiology, 412–413
  regulation of acid-base balance, 245–247
Reperfusion injury, 444, 445, 446
Reservoir bag, 177
Residual volume (RV), 26
Resistance, 19
Respiration
  clinical implications of altered respiration during anesthesia, 34
  insufficiency during anesthesia, 520–522
Respiratory acidosis. See also Acid-base balance
  causes, 248t
  compensatory changes, 249f, 250t
Respiratory alkalosis. See also Acid-base balance
  after cardiopulmonary resuscitation (CPR), 517
  causes, 248t
  compensatory changes, 249f, 250t
Respiratory rate
  as anesthetic depth indicator, 198–199
  cardiopulmonary resuscitation (CPR) and, 514
  monitoring, 219–220
  in neonatal patients, 496
Respiratory system
  inhalation anesthetic agent action and toxicity, 70
  lower airway dysfunction, anesthesia for patients with, 396–398
  induction, 397
  maintenance, 397
  mechanical ventilation, 397
  premedicants, 396–397
  recovery, 397–398
  opioid side effects, 103–104
  pharmacology of anesthetic drugs, 388–392
    analgesic drugs, 392
    induction drugs, 391
    maintenance drugs, 392
    sedatives and tranquilizers, 388–389, 391
  physiology (See Respiratory system physiology)
  pulmonary physiology alterations in pregnancy, 470t
  regulation of acid-base balance, 245
  upper airway dysfunction, anesthesia for patients with, 393–396
    induction, 394
    intubation, 394–395
    maintenance, 395
    preanesthetic preparation, 393–394
    recovery, 395–396
Respiratory system physiology, 25–34, 387–388
  apneic threshold, 31
  carbon dioxide transport, 30
  clinical implications of altered respiration during anesthesia, 34
  control of respiration, 27–28
  definitions, 26–27
  drug effect on control of ventilation, 31–33
    inhalants and injectable drugs, 32
    opioids, 32
    sedatives and hypnotics, 32–33
    tranquilizers, 32
    normal control mechanisms, 31
    oxygen transport, 28–30
    uneven ventilation and blood flow, schematic of, 29f
    ventilation-perfusion relationships during anesthesia, 33
Responses, defined, 85
Reticular formation, 86
Retrobulbar anesthesia, 353, 354
Reverse Trendelenburg position, 7, 429
Ring block, 357, 501
Risk, 9–14. See also Anesthetic risk
  anesthetic/sedation-related deaths, 10–11, 11t
  complications in anesthesia, 10t
  death causes, 11–12, 12t
  insurance claims, 12, 12t, 14
  timing of anesthetic/sedation-related deaths, 11
Rocuronium
  in liver disease patients, 427
  pharmacology, 79
Rodents. See also Laboratory mammal anesthesia
  anesthesia, general considerations in, 315–316
anesthetic delivery systems, 301
endotracheal tubes placement in, 308–309
fluid volumes for administration, 311t
gerbils, 317
hamsters, 317
injectable agents, 302–306, 303t–304t
IP (intraperitoneal) injection, 315, 317f
mice, 318
monitoring and intraoperative care, 306–314
neonatal, 314–315
physiological data, 301t
preanesthetic agents, 316t
rats, 318
routes of injection, 318t

**Ropivacaine. See also Local anesthetics**
in cesarean section patients, 474t
chirality, 329
doses for peripheral and epidural block procedures, 364t
epidural use, 376
infiltration anesthesia, 369
metabolism of, 343
properties, 332t
topical use, 369
trade name, structure, and main uses, 331t

**RV (residual volume), 26**

**Safety**
magnetic resonance imaging (MRI), 506–508, 508t
medical gas, 166–167
SA node. See Sinoatrial (SA) node
SaO₂ (arterial O₂ saturation), 201–203, 214–218, 217t
SBE (standardized base excess), 251, 256–257, 256t, 257t
Scavenging system
described, 171f, 183–185
negative pressure systems, 183–185

**Sedatives**
cardiovascular effects, 379–381
in liver disease patients, 424–425
in neonatal and geriatric patients, 493
in neurological disease patients, 402–403
in ocular patients, 464, 466t–467t
in orthopedic patients, 500
pharmacology, 44–50
alpha₁ adrenergic agonists, 44–47
alpha₂ adrenergic antagonists, 47–48
benzodiazepine antagonists, 50
benzodiazepines, 48–50
phenothiazines and butyrophenones, 44
preanesthetic use, 279, 282t
renal effects, 414–415
respiratory effects, 388–389, 391
ventilation, effect on control of, 32–33

**Seizures, management in perianesthetic period, 407**

**Septic shock, 478–480**

**Serotonin syndrome, 109**

**Sevoflurane**
for anesthesia induction, 286t
for anesthetic maintenance in patients with trauma and/or hemodynamic instability, 293t
biotransformation of, 66, 72
cardiovascular effects, 70, 380t
in cesarean section patients, 474t
compound A, 72, 415
decomposition to Compound A, 179–180
electroencephalographic effects, 69
for exploratory laparotomy, 443
in GI endoscopy patients, 440
hepatic effects, 72
in liver disease patients, 427
in obese patients, 451
ocular effects, 466t
physical and chemical characteristics, 58t, 59t
in renal disease patient anesthesia, 418t
renal effects, 72, 414t, 415
respiratory effects, 392

**Shock, 478–490**
analgesia, 486
antiarrhythmic therapy, 485, 486t
bicarbonate therapy, 485
cardiogenic, 479t, 483
cardiovascular support, 483–484
inotropes, 483, 484t
vasopressors, 483–484, 485t
classification of types, 479t
fluid options for volume resuscitation in hypovolemic, 482t
hemorrhagic, 480–481, 481t
neurogenic, 483
Index

**Phases of Syndrome**
- Septic, 478–480
- Systemic inflammatory response syndrome (SIRS), 478–480, 480t

**Shunts**
- Hypoxemia from, 388, 389t

**Shu points**, 139

**SIDS**
- See Strong ion difference (SID)

**SIDeff (effective SID)**, 255–256

**SIG (strong ion gap)**, 255–256, 257–258

**Simple acid-base disorders**, 248–249, 249f

**Simultaneous ventilation-compression (SVC)**, 515–516

**Sinoatrial (SA) node**
- Functioning of, 22
- Overdrive suppression, 22

**SIRS (systemic inflammatory response syndrome)**, 478–480, 480t

**Skeletal muscle**
- Inhalation anesthetic agent action and toxicity, 73
- Malignant hyperthermia (MH), 73

**Skunks**, 322–323

**Small mammal anesthesia**.
- See also Laboratory mammal anesthesia

**Laboratory mammal anesthesia**
- Aquatilis, 320
- Armadillos, 321–322
- Badgers, 323
- Bats, 320–321
- Chinchillas, 319
- Ferrets, 322
- Insectivora, 324–325
- Marmots, 320
- Marsupials, 324
- Mink, 322
- Monitoring and intraoperative care, 306–314
- Nutria, 320
- Prairie dogs, 319
- Procyonids, 323–324
- Rodents and rabbits, 315–319
- Skunks, 322–323
- Squirrels, 319
- Stoat, 323
- Straub tail response, 314
- Stress evaluation, preanesthetic, 4–5
- Stress response, pain inducement of, 149
- Stroke volume
  - Cardiac output and, 378–379
  - Inhalant anesthetic agent effect on, 70
- Strong acid, 241
- Strong base, 241
- Strong ion approach to acid-base analysis, 253–258, 254t
  - Base excess modification, 256–257, 256t, 257t
  - Effective SID modification, 255–256
  - Simplified SIG modification, 257–258

**Strong ion difference (SID)**
- Described, 253–255
- Effective SID modification, 255–256

**Strong ion gap (SIG)**, 255–256, 257–258

**ST segment**, 24

**Subarachnoid anesthesia**
- For cesarean section, 476
- Disadvantages of, 476

**Subarachnoid space**, 37
Substance P, 89–90, 101
Succinylcholine
  in cesarean section patients, 474t
  channel blockade, 77
  doses, 77t
  intracranial pressure (ICP) elevation with, 404
  muscle fasciculations, 77
  pharmacology, 78
  receptor desensitization, 77
  recovery from, 81
Sufentanil
  dosage ranges, 106t
  overview of, 111
Suffering, defined, 85
Sugar glider, 324
Superficial peroneal nerve block, 373f
Supraventricular tachycardia (SVT), 230–231
SVC (simultaneous ventilation-compression), 515–516
SvO2 (venous oxygen saturation), 203
Swallow reflex, as anesthetic depth indicator, 199
S wave, 24
Synergism, drug, 8
Systemic circulation, 17f
Systemic inflammatory response syndrome (SIRS), 478–480, 480t
Systemic vascular resistance (SVR)
  inhalant anesthetic agent effect on, 71
  mean arterial blood pressure (MAP) and, 208–209
  as measure of afterload, 25
Systolic arterial pressure, 481t
Tachyarrhythmias, managing as anesthetic complications, 228t, 230–231
Tachycardia
  managing anesthetic complications, 228t, 230–231
  with pheochromocytoma, 456
Tachyphylaxis, local anesthetics and, 348
Tachypnea, 26
Tafonius ventilator, 187, 188f
Tapendadol, 131
Tapotement, 143–144
TBW (total body water), 258
Tear production, 462, 468
TEE (transesophageal echocardiography), for cardiac output estimation, 213
Telazol. SeeTiletamine/zolazepam (Telazol)
Telencephalon, 35
Temperature
  effects on acid-base balance, 247
  managing anesthetic complications
    hyperthermia, 239
    hypothermia, 238–239
  monitoring, 225
Temperature compensation, vaporizer, 172
TENS. See Transcutaneous electrical nerve stimulation (TENS)
Tepoxalin
  dosage ranges, 126t
  mechanism of action, 118
  ocular effects, 467t
  for oral postoperative analgesics, 289t
  overview of, 127
Tetracaine. See also Local anesthetics
  corneal desensitization, 369
  metabolism of, 343
  properties, 332t
  topical use, 349
  trade name, structure, and main uses, 331t
Thermometer, 225
Thermoregulation
  assessment in small mammals, 309
  monitoring, 225
Thiobarbiturates
  apnea and, 521
  greyhounds and, 291
  in neurological disease patients, 403
  renal effects, 415
Thiobutabarbitral, in laboratory mammals, 305
Thiopental
  for anesthesia induction, 286t
  cardiovascular effects, 380t
  in cesarean section patients, 473t
  dysrhythmias from, 512
  in GI endoscopy patients, 440
  in liver disease patients, 426
  in neonatal and geriatric patients, 494
  in obese patients, 451
  ocular effects, 466t
  in orthopedic patients, 500
  perivascular injection, 520
  pharmacology, 52, 53f
  renal effects, 414t
  in respiratory disease patients, 394
Thiopentone, in laboratory mammals, 304t
Third-degree AV block, 229, 229f
Thoracic auscultation, of heart rate, 205
Thoracic drain placement, 505
Thoracic pump theory, 514
Thoracostomy tube, 500
Thoracotomy
  emergency, 518
  pain management, 518
Thyroid gland, 459–460
Tibial nerve block in cats, 371, 373f
Tidal volume (TV)
  as anesthetic depth indicator, 198–199
  defined, 26
  factors that affect delivered, 193–194
  monitoring, 219, 220
Tiletamine
  cardiovascular effects, 380t, 381
  respiratory effects, 391
Tiletamine/zolazepam (Telazol)
  for anesthesia induction, 286t
  in cesarean section patients, 473t
  described, 48, 56–57
  in intramuscular anesthetic protocol in cats, 285t
  in intramuscular anesthetic protocol in dogs, 284t
  in laboratory mammals, 302, 303t–304t, 305
  in liver disease patients, 426
  in neurological disease patients, 403
  ocular effects, 466t
  in orthopedic patients, 500
  in respiratory disease patients, 397
Timolol, ophthalmic indications and side effects of, 465t
TLC (total lung capacity), 27
Tolazoline, 47
Tolentaonic acid
  dosage ranges, 126t
  overview of, 127
Tonicity, 259
Topical anesthesia
  in cats, 368–369
  in dogs, 349–350
  in ocular patients, 465, 468
Total body water (TBW), 258
Total lung capacity (TLC), 258
Total solids, serial assessments of, 267
Total ventilation (VT), 218
Toxicity, of local anesthetics, 343–348
T-piece, use in small mammals, 309
Tracheal chondromalacia, 526
Tracheal mucosal injury, during anesthesia, 526
Tracheal rupture, 497, 526
Traditional Chinese medicine (TCM), 131–140. See also Acupuncture
Tramadol
  analgesia, 130–131
  for chronic pain, 156
  in dental patients, 498
  dosage ranges, 129t
  for oral postoperative analgesics, 289t
Tranquilizers
  cardiovascular effects, 379–381
  effect on control of ventilation, 32
  in neurological disease patients, 402–403
  respiratory effects, 388–389, 391
Transcellular fluid compartment, 258
Transcutaneous electrical nerve stimulation (TENS)
  for postoperative pain control, 139
  rehabilitation therapy, 145–146
Transduction, nociception and, 98
Transesophageal echocardiography (TEE), for cardiac output estimation, 213
Traumatized patients, 477–490
  anesthetic drug selection for, 292, 292t, 293t
  anesthetic management, 486–490
  anesthetic induction, 487
  anesthetic maintenance, 488
  fluid therapy and cardiovascular support, 488
  mechanical ventilation, 489
  patient monitoring, 488
  preanesthetic period, 486–487
  recovery, 490
  regional anesthesia, 489–490
  general considerations, 477–478
  shock, 478–486
Trendelenburg position, 7
Tribromoethanol, in laboratory mammals, 303t, 306
Tricyclic antidepressants, for chronic pain, 156
Trigeminal nerve, desensitization of, 353
Trigeminal system, nociception and, 88
Index

Trigeminovagal reflex, 464
Tubing, breathing circuit, 176–77
TV. See Tidal volume (TV)
T wave, 24

Ulnar nerve block in cats, 371, 372f
Ultrasound
described, 508
guided liver biopsy, 428
therapeutic, 145
Universal F-circuit, 177
University of Melbourne Pain Scale (UMPS), 95

Upper airway dysfunction, anesthesia for patients with, 393–396
induction, 394
intubation, 394–395
maintenance, 395
preanesthetic preparation, 393–394
recovery, 395–396

Uptake, of inhalation anesthetic agents, 65, 66f
Urethane, in laboratory mammals, 303t, 305
Urethral obstruction, 420
Urine output, use in fluid balance assessment, 267
Uroperitoneum, 420
USCOM monitor, 213

Uterine blood flow during pregnancy, 469–470

Vₐ. See Alveolar ventilation (Vₐ)
Vaporizer, 171–173
back pressure, 172–173
calculation of anesthetic concentration delivered by, 62, 63f
description, 171–172
for desflurane, 173
filler port, 173
flow rate, 172
magnetic resonance imaging (MRI) effects on, 405

Vasoconstrictors, with local anesthetics, 336–337

Vasopressin
for cardiopulmonary resuscitation (CPR), 516–517
for cardiovascular support, 485t
deficiency in diabetes insipidus, 457–458

Vasopressors
in neurological disease patients, 403–404
for shock, 483–484, 485t

Vₐ. See Tidal volume (TV)

Vecuronium
in cesarean section patients, 474t
doses, 77t
in liver disease patients, 427
pharmacology, 79
Vedaprofen, 127

Veins, 16
Venous admixture, 33
Venous oxygen saturation (SvO₂), 203
Venous system, as blood reservoir, 16

Ventilation
dead space (Vₐ), 218
drug effect on control of, 31–33
inhalants and injectable drugs, 32
opioids, 32
sedatives and hypnotics, 32–33
tranquilizers, 32
key factors relating to, 203f
mechanical
in lower airway dysfunction patients, 397
in traumatized and critically ill patients, 489
monitoring, 218–225
objective methods, 219–225
arterial partial pressure of CO₂, 220–221
end-tidal CO₂ (ETCO₂), 221–225, 221f, 223f, 224f, 224t
respiratory rate, 219–220
tidal volume, 220
subjective methods, 219
patient evaluation, 6

Ventilation-perfusion
functional residual capacity (FRC) decrease and, 521–522
relationships during anesthesia, 33

Ventilation/perfusion (V/Q) mismatch
hypoxemia and, 234, 235t, 236, 388, 389t
measurement of, 33
Ventilators, 187–195
alarms, 194
  airway pressure, 194
  low driving gas pressure, 194
control of driving gas, 192
described, 187–188
dual-circuit, 188–192, 190f
  bellows, 189, 191
  exhaust valve, 191–192
  housing, 191
  spill valve, 192
  ventilator hose connection, 192
factors effecting delivered tidal volume, 193–194
  compliance and compression volumes, 194
  fresh gas flow, 193–194
  leaks, 194
hose connection, 192
piston-driven, 187–188, 188f
rolling diaphragm system of Tafonius, 188f
setup and monitoring, 195
switch engagement, 193f
Ventilometer, 220
Ventricular fibrillation, cardiac arrest and, 513, 517
Ventricular premature contractions (VPCs), 230, 230f, 512
Vent valve, 192
Venules, 16
Verapamil
  intravenous dose for heart rate/rhythm abnormalities, 228t
  for tachyarrhythmias, 231
Visceral inflammation/injury, chronic pain and, 148t
Visceral pain, 87
Visual analog scale (VAS), of pain diagnosis, 4, 94, 95f
Vital capacity (VC), 27
VO₂ (oxygen consumption), 202–203
Volatile acid, 241
Volatile anesthetic agents. See Inhalant anesthetic agents
Voles, 320
Vomiting
  acupuncture for, 139–140
  opioids and, 103
VPCs (ventricular premature contractions), 230, 230f, 512
Vₖ (total ventilation), 218
Waste gas scavenge system, 183–185
Water-based massage, 144
Weak acid, 241
Weak base, 241
Weasel, 323
Whole blood transfusion, 273, 310
Wide-dynamic-range (WDR) neurons, 89
Windkessel effect, 16
Windup, 89, 90, 90f, 92
World Health Organization (WHO), chronic pain management approach, 151–152, 151f
Wright’s Respirometer, 220
Xylazine
  described, 47
  dysrhythmias from, 512
  in intramuscular anesthetic protocol in cats, 285t
  in laboratory mammals, 302, 303t–304t
  renal effects, 414
  in rodents and rabbits, 316t
Yohimbine, 47
Zolazepam. See Tiletamine/zolazepam (Telazol)
Zygomatic nerve, desensitization of, 352f, 353